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Multiple myeloma (MM) is a fatal malignant proliferation of antibody-secreting bone marrow (BM) 
plasma cells (PCs) characterized by a wide clinical spectrum and a profound genomic instability. 
Concerning in particular the mutational landscape, recent next generation sequencing (NGS) 
studies in MM patients indicated the lack of a universal driver mutation but several recurrently 
mutated genes belonging to key pathways involved in the disease, such as the MAP-kinase 
pathway.  
MM characterization currently depends on BM aspirates for mutational analysis. However, this 
approach might not capture the putative spatial and genetic heterogeneity of the disease, and 
imposes technical hurdles that are limiting its transfer in the routine and clinical grade diagnostic 
laboratory, restricting also the possibility of longitudinal monitoring of disease molecular markers. 
Nevertheless, recent data produced in solid cancers indicate that circulating tumor DNA into the 
peripheral blood (PB) can be used as source of tumor DNA to provide information about tumor 
mass, residual disease and tumor genotype, with obvious advantages in terms of accessibility. 
Based on the previous observations, the aims of the project were: (i) the evaluation of the incidence 
of mutations in MM driver genes (KRAS, NRAS, TP53, BRAF, FAM46C and DIS3) in a large and 
representative cohort of patients at different stages of PC dyscrasia (132 MM and 24 primary PC 
leukemia (pPCL) cases, both at onset, and 11 secondary PCL (sPCL) patients); (ii) the comparison of 
the mutational profiling of circulating cell free DNA (cfDNA) and BM derived DNA in a small series 
of patients representative of different clinical stages of PC tumors.  
Specifically, we evaluated, by means of deep NGS, the incidence of mutations in BRAF (exons 11 
and 15), NRAS (exons 2 and 3) and KRAS (exons 2-4), DIS3 in the PIN (exons 1-4) and RNB (exons 10-
18) functional domains, TP53 (exons 4-9) and FAM46C (exon 2).  
Overall, the MAPK pathway resulted affected in 60.1% of the patients (63.6% of those with sPCL, 
59.8% of those with MM, and 41.7% of those with pPCL). In particular, 12% of patients were found 
mutated in BRAF, 23.9% in NRAS, and 29.3% in KRAS. DIS3 mutations were found, respectively, in 
18.5% of MM patients at diagnosis, 25% of pPCLs and 30% of sPCLs, occurring more frequently in 
IGH-translocated/nonhyperdiploid patients. Twenty-four tumour-specific mutations were 
identified in FAM46C affecting 18/162 (11%) patients. In particular, the frequency of FAM46C 
mutations was 11.7% in newly diagnosed MM, 4.2% and 20% in primary and secondary PCL, 
respectively. TP53 was mutated in 4/129 (3%) MM, 6/24 (25%) pPCL, and 2/10 (20%) sPCL cases. A 
similar increase in prevalence associated with disease aggressiveness (5%, 29.2% and 44%, 
respectively) was observed for TP53 deletion.  
In all analyzed genes, co-existing mutations tended to occur at different variant allele frequencies 
(VAFs), thus supporting the occurrence of tumor subclones.  
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Longitudinal analysis at diagnosis and relapse in a subset of 19 cases including both MM and PCL 
cases, revealed different mutation patterns in BRAF/NRAS/KRAS. We observed the presence of 
clonal variants at both time-points; the acquisition/clonal expansion of variants in the later sample; 
and even the disappearance of variants at relatively high VAF values, but always concurrently with 
the emergence/clonal expansion of an additional mutation in another gene of the MAPK pathway. 
These longitudinally analysis highlighted some instances of increasing DIS3 mutation burden during 
disease progression. On the contrary, in FAM46C we observed a reduction or disappearance of 
three primary mutations with a quite constant VAF in cases at onset; instead, we noticed the 
acquisition of TP53 mutations in three of the nineteen cases analyzed at relapse.  
The majority of BRAF/DIS3/FAM46C variants in mutated cases were comparably detectable at 
transcriptional level. Overall, the finding that FAM46C mutated alleles had detectable biological 
expression, and in some cases seemed to be even preferentially transcribed, suggests that the 
mutations identified herein may have functional implications.  
The study on cfDNA as an accessible source of genomic material in MM patients was based on a 
series of 28 patients with PC disorders, of whom we collecteded: (1) cfDNA isolated from plasma; 
(2) tumor genomic (g)DNA from CD138+ purified BM PCs for comparative purposes, and (3) 
germline gDNA extracted from PB granulocytes, to filter out polymorphisms. CAPP-seq ultra-deep 
targeted NGS approach was performed to genotype a gene panel specifically designed to maximize 
the mutation recovery in PC tumors. Overall, within the interrogated genes, 18/28 (64%) patients 
had at least one non-synonymous somatic mutation detectable in cfDNA. Consistent with the 
spectrum of mutated genes in PC disorders, plasma cfDNA genotyping revealed somatic variants of 
NRAS (25%); KRAS (14%); TP53, TRAF3 and FAM46C (11%, respectively); CYLD and DIS3 (7%, 
respectively); and BRAF and IRF4 (4%, respectively). cfDNA genotyping correctly identified 72% of 
mutations (n=28/39) discovered in tumor PCs and, overall, the VAFs in plasma samples correlated 
with those in tumor biopsies. Notably, the remaining mutations not discovered in cfDNA had a low 
representation in the purified BM PCs (median VAF=2.5%). ROC analysis showed that cfDNA 
genotyping had the highest sensitivity (100%) if mutations were represented with a VAF >5% in 
purified BM PCs. 
The results of our study confirm and extend previous published evidence that MAPK pathway 
activation is recurrent in MM, and the finding that it is mediated by BRAF mutations in a significant 
fraction of patients has potentially immediate clinical implications. Furthermore, gene expression 
profiling analysis in DIS3-mutated patients identified a transcriptional signature suggestive for 
impaired RNA exosome function. Our data further support the pathological relevance of DIS3 
mutations in PC dyscrasia and suggest that DIS3 may represent a potential tumor suppressor gene 
in such disorders. It is also strengthened the growing evidence that FAM46C is involved in the 
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pathogenesis of MM as a potential tumour suppressor, although its role remains to be clarified. 
Our outcomes also confirm that TP53 mutations are rare in MM at presentation and rather 
represent a marker of progression, similarly to del(17p); however, their occurrence even in absence 
of deletions supports the importance of their assessment in patients with PC dyscrasia, in terms of 
both risk stratification and therapeutic implications.  
 Our results demonstrate as well that cfDNA genotyping is a feasible, non-invasive, real-time 
approach able to detect clonal and subclonal somatic mutations represented in at least 5% of alleles 
in tumor PCs, thus supporting the advisable introduction of this method in clinical trials monitoring 
PC dyscrasia. 
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Il mieloma multiplo (MM) è una proliferazione maligna fatale delle plasmacellule (PC) secernenti 
anticorpi del midollo osseo (BM), caratterizzata da un ampio spettro clinico e da una profonda 
instabilità genomica. Per quanto riguarda in particolare il panorama mutazionale, recenti studi di 
sequenziamento di nuova generazione (NGS) nei pazienti con MM hanno indicato la mancanza di 
una mutazione pilota universale, ma diversi geni mutati ricorrenti appartenenti a percorsi chiave 
coinvolti nella malattia, come la via MAP-chinasi. La caratterizzazione del MM attualmente si basa 
sull'analisi mutazionale effettuata sugli aspirati di BM. Tuttavia, questo approccio potrebbe non 
catturare la presunta eterogeneità spaziale e genetica della malattia e imporre ostacoli tecnici che 
ne limitano il trasferimento nel laboratorio diagnostico di routine e clinico, riducendo anche la 
possibilità di un monitoraggio longitudinale dei marcatori molecolari della malattia. Ciononostante, 
recenti dati relativi a cancri solidi indicano che il DNA circolante nel sangue periferico (PB) può 
essere usato come fonte di DNA tumorale per fornire informazioni sulla massa tumorale, sulla 
malattia residua e sul genotipo tumorale, con ovvi vantaggi in termini di accessibilità. Sulla base 
delle osservazioni precedenti, gli obiettivi del progetto erano: (i) la valutazione dell'incidenza delle 
mutazioni nei geni “driver” del MM (KRAS, NRAS, TP53, BRAF, FAM46C e DIS3) in una coorte ampia 
e rappresentativa di pazienti a diversi stadi di discrasia plamacellulare (132 MM e 24 casi di 
leucemia plasmacellulare primaria (pPCL), entrambi all'esordio, e in 11 pazienti con PCL secondaria 
(sPCL)); (ii) il confronto del profilo mutazionale del DNA libero da cellule circolante (cfDNA) e del 
DNA derivato dal BM in una piccola serie di pazienti rappresentativa di diversi stadi clinici di tumori 
plasmacellulari. 
Nello specifico, abbiamo valutato, mediante NGS ad alta profondità, l'incidenza di mutazioni in 
BRAF (esoni 11 e 15), NRAS (esoni 2 e 3) e KRAS (esoni 2-4), DIS3 nei domini funzionali PIN (esoni 1-
4) e RNB (esoni 10-18), TP53 (esoni 4-9) e FAM46C (esone 2). 
Complessivamente, la via MAPK è risultata affetta da mutazioni nel 60,1% dei pazienti (63,6% di 
quelli con sPCL, 59,8% di quelli con MM e 41,7% di quelli con pPCL). In particolare, il 12% dei pazienti 
è stato trovato mutato in BRAF, il 23,9% in NRAS e il 29,3% in KRAS. Mutazioni di DIS3 sono state 
riscontrate, rispettivamente, nel 18,5% dei pazienti con MM alla diagnosi, nel 25% delle pPCL e nel 
30% delle sPCLs, con una maggior frequenza nei pazienti IGH-traslocati/non iperdiploidi. In FAM46C 
sono state identificate 24 mutazioni tumore-specifiche interessanti 18/162 (11%) pazienti. In 
particolare, la frequenza delle mutazioni di FAM46C era dell'11,7% nei MM di nuova diagnosi, e del 
4,2% e del 20%, rispettivamente, nelle PCL primarie e secondarie. TP53 era mutato in 4/129 (3%) 
MM, 6/24 (25%) casi di pPCL e 2/10 (20%) di sPCL. Una frequenza simile associata all'aggressività 
della malattia (5%, 29,2% e 44% rispettivamente) è stata osservata per la delezione di TP53. 
In tutti i geni analizzati, le mutazioni coesistenti tendevano a verificarsi a diverse frequenze di 
varianti alleliche (VAFs), sostenendo in tal modo la presenza di subcloni tumorali. 
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L'analisi longitudinale alla diagnosi e alla recidiva in un sottogruppo di 19 pazienti, che includeva 
casi di MM e PCL, ha rivelato diversi modelli di mutazione in BRAF/NRAS/KRAS. Abbiamo osservato 
la presenza di varianti clonali ad entrambe le tempistiche; l'acquisizione/espansione clonale delle 
varianti nel campione successivo; e persino la scomparsa di varianti a valori di VAF relativamente 
alti, ma sempre in concomitanza con l'emergenza/l’espansione clonale di un'ulteriore mutazione in 
un altro gene della via MAPK. Queste analisi longitudinali hanno evidenziato alcuni casi di aumento 
del carico di mutazione di DIS3 durante la progressione della malattia. Al contrario, in FAM46C 
abbiamo osservato una riduzione o scomparsa di tre mutazioni primarie con una VAF abbastanza 
costante nei casi all'esordio; invece, abbiamo notato l'acquisizione di mutazioni di TP53 in tre dei 
diciannove casi analizzati in recidiva. 
La maggior parte delle varianti di BRAF/DIS3/FAM46C nei casi mutati erano comparabilmente 
rilevabili a livello trascrizionale. Complessivamente, la scoperta che gli alleli mutati di FAM46C 
avevano un'espressione biologica rilevabile e, in alcuni casi, sembrava addirittura trascritta 
preferenzialmente, suggerisce che le mutazioni qui identificate possono avere implicazioni 
funzionali. 
Lo studio sul cfDNA come fonte accessibile di materiale genomico nei pazienti con MM è stato 
condotto su una serie di 28 pazienti con disordini plasmacellulari, dei quali abbiamo raccolto: (1) 
cfDNA isolato dal plasma; (2) DNA genomico (gDNA) tumorale da PC di BM CD138+ purificate, per 
scopi comparativi e (3) gDNA germinale estratto da granulociti da PB, per filtrare i polimorfismi. 
L'approccio “NGS CAPP-seq ultra-deep targeted” è stato eseguito per genotipizzare un pannello 
genico specificamente progettato per massimizzare l’identificazione delle mutazioni nei tumori 
plasmacellulari. Complessivamente, all'interno dei geni interrogati, 18/28 (64%) pazienti avevano 
almeno una mutazione somatica non sinonima rilevabile nel cfDNA. 
Coerentemente con lo spettro dei geni mutati nei disordini delle PC, la genotipizzazione del cfDNA 
nel plasma ha rivelato varianti somatiche di NRAS (25%); KRAS (14%); TP53, TRAF3 e FAM46C (11%, 
rispettivamente); CYLD e DIS3 (7%, rispettivamente); e BRAF e IRF4 (4%, rispettivamente). La 
genotipizzazione del cfDNA ha identificato correttamente il 72% delle mutazioni (n=28/39) rilevate 
nelle PC tumorali e, nel complesso, le VAFs nei campioni di plasma correlavano con quelle delle 
biopsie tumorali. Va notato che le rimanenti mutazioni non rilevate nel cfDNA avevano una bassa 
rappresentazione nelle PC midollari purificate (VAF mediana=2,5%). L'analisi ROC ha mostrato che 
la genotipizzazione di cfDNA aveva la massima sensibilità (100%) se le mutazioni erano 
rappresentate con una VAF> 5% nelle PC di BM purificate. 
I risultati del nostro studio confermano ed estendono le evidenze pubblicate in precedenza che 
l'attivazione del pathway delle MAPK è ricorrente nel MM, e la scoperta che essa è mediata da 
mutazioni in BRAF in una frazione significativa di pazienti ha implicazioni cliniche potenzialmente 
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immediate. Inoltre, l'analisi del profilo di espressione genica in pazienti DIS3-mutati ha identificato 
una “signature” trascrizionale suggestiva per la riduzione della funzione dell’esosoma dell'RNA. I 
nostri dati supportano ulteriormente la rilevanza patologica delle mutazioni di DIS3 nelle discrasie 
plasmacellulari e suggeriscono che DIS3 possa rappresentare un potenziale gene soppressore del 
tumore in tali disordini. E 'anche rafforzata la crescente evidenza che FAM46C sia coinvolto nella 
patogenesi del MM come potenziale gene oncosoppressore, anche se il suo ruolo rimane da 
chiarire. I nostri risultati confermano anche che le mutazioni di TP53 sono rare nel MM all’esordio 
e rappresentano piuttosto un marker di progressione, analogamente alla del(17p); tuttavia, il loro 
verificarsi anche in assenza di delezioni supporta l'importanza della loro valutazione in pazienti con 
discrasia plasmacellulare, in termini sia di stratificazione del rischio sia di implicazioni terapeutiche. 
I nostri risultati dimostrano anche che la genotipizzazione di cfDNA è un approccio fattibile, non 
invasivo, in tempo reale in grado di rilevare mutazioni somatiche clonali e subclonali rappresentate 
in almeno il 5% degli alleli nelle PC tumorali, supportando così la consigliabile introduzione di questo 
metodo negli studi clinici che monitorano le discrasie plasmacellulari. 
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Multiple myeloma (MM) represents a heterogeneous hematologic malignancy that occurs 
generally in the elderly population (median age at diagnosis ~70 years). Similarly to many other 
neoplastic diseases, also MM incidence is progressively increasing worldwide, mainly due to the 
major improvements in people life expectancy, leading to a marked increase in longevity. 
Symptomatic MM is generally preceded by an indolent expansion of clonal plasma cells, known as 
monoclonal gammopathy of undetermined significance (MGUS) and/or smoldering MM (sMM)1-4. 
These entities are completely asymptomatic and usually their diagnosis is made occasionally. 
Generally, the prevalence of MGUS and sMM progressively increases in the elderly with more than 
5% prevalence among general population older than 70 years1, 3. The majority of MGUS and a part 
of sMM remains commonly stable and asymptomatic over the time. Nevertheless, in some patients, 
those indolent entities progress in symptomatic MM. The MGUS/sMM transformation into MM is 
clinically characterized by lytic bone disease, anaemia, renal failure, hypercalcemia, and 
susceptibility to bacterial infections. Which biological features and why some MGUS/sMM remain 
totally asymptomatic for decades whereas others progress in symptomatic MM is at present 
unknown, but the current hypothesis is the accumulation by the time of “malignant” genetic events, 
similarly to what happens in other cancers such as melanoma1, 3. 
 
 
Cell of Origin: The Plasma Cell 
The MM normal counterpart is the plasma cell (PC), which represents the final differentiation stage 
of B cells. The first steps of differentiation occur within the bone marrow (BM) where different 
complex processes lead to the rearrangements and editing of the heavy chain immunoglobulin (Ig) 
gene (IGH)5. This gene (2 Mb) encodes a very large protein, presenting four major domains: the 
variability domain (VH), the diversity domain (DH), the joining domain (JH), and the constant 
domain. The first rearrangements are DNA stochastic and antigen independent deletions combining 
one of the DH segments to one of the six JH segments. If molecularly productive, the pro-B cell 
continues its differentiation processes by combining this DH-JH segment with a VH segment. This 
process is regulated by the recombination activating genes (RAG1 and RAG2), encoding for specific 
enzymes that recognize precise DNA motifs within the DH, JH, and VH segments. If these 
rearrangements are in frame, or “productive”, the pre-B cell will then rearrange the light chain 
genes, Ig kappa locus (IGK) and Ig lambda locus (IGL). The IGK is rearranged for first and, if the result 
is productive, the mature B cell will then be able to produce IgMk, generally expressed at the B-cell 
surface. If this process fails, the B-cell will then rearrange the IGL gene, leading to the production 
of an IgM. At the end of V(D)J recombination, B cells are able to express a functional B cell receptor 
(BCR) and subsequently they migrate to the secondary lymphoid organs (such as lymph nodes, 
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tonsils, and spleen). Here, interacting with an antigen, naive B cells are activated by interaction with 
CD4+ T cells in the T cell-rich area of the lymphoid tissues and aggregate into primary follicles to 
form germinal centres (GCs)6, 7. In the GC, B-cells are involved in two main immunoglobulin gene 
remodelling processes — namely, somatic hypermutation (SHM) and class-switch recombination 
(CSR) — in order to generate cells with the highest antigen-affinity antibodies of different isotype 
classes8. The GC emerges as a crucible in genesis of MGUS and MM via a distinctive pathway in 
which the cell of origin is targeted by on-going SHM9.  
SHM and CSR are driven by a specific enzyme called activation induced deaminase (AID) which 
represents the pivotal player of all GC reactions. In the first process, AID generates a variable and 
stochastic number of mutations within the VDJ segment. Only B-cells with mutations improving the 
specificity of the antibody for the antigen will survive, the others are removed via apoptosis. In the 
CSR process, AID recombines specific DNA segments known as switch regions with deletion of the 
inter switch region DNA, guarantying the expression of different Ig, either IgG, IgA, or IgE. After 
these processes, the B-cell maturation ends with the generation of both PCs and memory B cells 
(Figure 1). The dysregulation of AID hyper mutation activity and ability to break and recombine 
different DNA segments may generate a wide range of abnormal B cells that, if not promptly 
removed, may develop different post GC lymphoproliferative disorders such as different B-cell 
lymphomas, chronic lymphocytic leukemia and MM5. 
 
 
Figure 1. B-cell maturation model through the germinal centre5. 
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PCs are characterized by strong BM dependence for survival and growth. The immunophenotype 
of MM cells resembles that of normal, terminally differentiated, long-lived BMPC (CD19–, CD20–, 
CD45–, CD138+). In contrast to normal long-lived PCs, MM cells maintain some potential for an 
extremely low rate of proliferation, usually with only just a few per cent of cycling cells, until 
advanced stages of the disease10. 
 
 
Multi-step clinical course and pathogenesis  
MM affects antibody‐secreting BMPCs and is characterized by a wide clinical spectrum ranging from 
the presumed pre-malignant condition of MGUS to sMM, frank and symptomatic MM, and extra-
medullary myeloma/plasma cell leukemia (PCL). MGUS, like MM, produces a typical M-spike 
(generally non-IgM) by serum protein electrophoresis or free light chain in the urine. The MGUS 
condition is age dependent, affects about 4% of individuals over the age of 50, and can progress to 
MM at average rates of 1% per year11, 12. MGUS can be discriminated from MM for having a M-spike 
of <30 g/L, less than 10% of tumor cells among BM mononuclear cells, and no end organ damage 
or other symptoms. Progression of MGUS to sMM and symptomatic MM is combined with an 
expanding BM tumor bulk and increasingly severe organ impairment or symptoms2. 
Notwithstanding the marked dependence of MM cells on the BM tumor microenvironment, in the 
advanced stages of the disease the more aggressive tumors may sometimes spread to 
extramedullary locations, such as spleen, liver, and extra-cellular spaces. Extramedullary MM 
(EMM) can also manifest a leukemic phase, which is classified as secondary or primary PCL, based 
on the presence or absence of a preceding intramedullary MM. Most of the available human 
myeloma cell lines (HMCLs) have been generated from EMM or PCL tumors and represent a 
renewable source of the oncogenic events involved in initiation and progression of the most 
aggressive end-stage MM tumors13, 14 (Figure 2). 
 
 
Figure 2. Multi-step molecular pathogenesis of MM. Progression through the different stages of 
the desease. 
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To date, MM diagnosis follows the criteria established by the International Myeloma Working 
Group in 200315 subsequently updated in 200916. Osteolytic bone lesions and/or compression 
fractures detected on routine radiographs, magnetic resonance imaging, or computed tomographic 
scans are the most characteristic markers of end-organ damage in myeloma. Anemia (occurring in 
70% of patients), renal failure (50%), and hypercalcemia (25%) are the other established markers 
of end-organ damage. The presence of one or more of these four markers that is felt to be related 
to the underlying PC disorder is required for the diagnosis of the disease (Table 1). 
 
Table 1. Mayo Clinic diagnostic criteria for selected clonal plasma cell disorders. 
 
 
 
Plasma Cell Leukemia 
PCL is the most aggressive presentation of the PC tumors, characterized by circulating PCs >2×109/L 
in peripheral blood or by a relative plasmacytosis >20% of blood leukocytes17, 18. While primary 
disease (pPCL) shows as de novo leukemia, secondary leukemic transformation (sPCL) arises from 
pre-existing MM, probably as a consequence of clonal transformation. The occurrence of PCL is a 
rare event: the incidence of sPCL in MM patients is only of 1.8–4%, similar to the occurrence of 
pPCL. Around 60% of patients present a primary form and the remaining 40% occur as complication 
during the course of MM19. The median age of patients with pPCL ranges between 52 and 65 years, 
about 10 years younger than the median age of 65 to 70 years observed in the general myeloma 
population and in sPCL. 
 
 
Genetic architecture of Multiple Myeloma 
Several pieces of evidence support the hypothesis that the oncogenic transformation in MM occurs 
within secondary lymphoid organs. MM is characterized by an abnormal proliferation of aberrant 
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PCs that generally feature a high rate of somatic mutations on IGH/IGK/IGL, suggesting that these 
cells were exposed to the AID activity and SHM GC process. In addition, the nature of monoclonal 
Ig is essentially IgG and IgA, rarely IgD or IgM, being another indirect evidence of MM plasma cell 
exposure to CSR. A further proof that straightened the MM post GC origin, is represented by the 
recurrence of genomic events, in particular translocations, involving the IGH gene3 (see Table 2). 
Interestingly, from the analysis of IGH translocation breakpoints, it was shown that the t(4;14) 
largely involves the switch regions, suggesting errors during the CSR process6, 20 whereas the 
t(11;14) may result from errors during the SMH20. Basing on the breakpoints analysis, a recent paper 
from the UK group3 suggested that ~20% of t(11;14) and t(14;16) translocations may take place 
within the BM during the maturation IGH rearrangements (Figure 3). 
 
Table 2. Genetic events underlying the initiation and progression of myeloma to plasma cell 
leukaemia3. 
 
 
It is still not clear which and how specific pre GC events may lead to a post GC disease. However, it 
was described that >4% of MM patients have two unrelated clones with different VDJ 
rearrangements, suggesting the potential existence of an aberrant genomic process during the 
early phase of B-cell maturation. Differently from other cancers, MM is not characterized by 
common and distinct “driver” events (i.e substitution). The only recurrent and potentially driver 
MM events are hyperdiploidy, IGH translocations and specific deletions. The hyperdiploid (HRD) 
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cytogenetic profile is observed in up to 55% of the patients21-25, with 48–75 (mostly 49–56) 
chromosomes, usually with extra copies of three or more specific odd chromosomes (3, 5, 7, 9, 11, 
15, 19, and 21). 
 
 
Figure 3. Summary of translocation events in myeloma. Translocations occur between the IGH 
locus and all main partner chromosomes through CSR in the germinal center. t(11;14) and 
t(14;20) subgroups also have other mechanisms of developing translocations through receptor 
revision in the germinal center or through DH-JH recombination at the early pro–B-cell stage20. 
 
Hyperdiploidy is probably due to an aberrant missegregation of chromosomes during mitosis, but 
the mechanisms responsible for these events are still unknown. In any case, HRD patients seem to 
have a better prognosis than non-HRD patients26. 
The second pathway is based on IGH translocations, observed in 40% to 50% of the patients and 
almost all the HMCLs27, 28. Generally, IGH translocations are mutually exclusive with HRD 
cytogenetic profile. Some of these 14q32 translocations are recurrent (Table 2), others being 
apparently random29. These rearrangements generally determine an overexpression of the partner 
genes under dependence of the strong IGH enhancers, leading to overexpression of the targeted 
proteins. The most frequent one is the t(11;14)(q13;q32), observed in 15%-20% of the patients30. 
The t(11;14) dysregulates the CCND1 gene, leading to its overexpression. In frequency, the second 
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recurrent IGH translocation is the t(4;14)(p16;q32), observed in 10%-15% of the patients. This 
translocation is very peculiar in B-cell malignancies, by disrupting and upregulating two genes, 
FGFR3 and MMSET/WHSC1, creating a fusion transcript with this latter gene31, 32. FGFR3 is an 
oncogene activated by mutations in several solid tumor types, and it is upregulated only in 70% of 
MM patients harbouring the t(4;14), owing to an unbalanced translocation with loss of the 
telomeric part of chromosome 4, bearing FGFR333-35. This finding suggests that the main molecular 
target of the translocation is MMSET whose upregulation leads to methylation of several proteins 
in the genome36. Other recurrent translocations are rarely observed in more than 3% of the 
patients, such as the t(14;16)(q32;q23), which dysregulates the MAF oncogene31, 37; the 
t(14;20)(q32;q11), dysregulating the MAFB oncogene38; or the t(6;14)(p21;q32), which upregulates 
the CCND3 gene21. Interestingly, some recent next generation sequencing (NGS) data have 
suggested that other translocations IGH-independent may be involved in MM pathogenesis. The 
most important example is represented by translocations involving MYC locus, that are generally 
considered as secondary events39. Translocation between 8q24 (MYC) and 14q32 (IGH) is 
detectable in 5-10% of patients, but approximately 50% of all MM are characterized by a 
rearrangement involving MYC. Apart IGH, the most frequent MYC-translocation partners are IGK, 
IGL, XBP1, FAM46C, CCND1 and KRAS39. Overall, these translocations lead to an aberrant MYC 
overexpression. This is one of the main proofs of the presence of other IGH-independent 
translocations that significantly contribute to the final proliferation and behaviour of MM. All these 
non-IGH translocations are generally supposed to be secondary events in the MM oncogenesis3. 
The main reason supporting this hypothesis is that most of them are often observed only at 
subclonal levels, in contrast to IGH translocations, which are usually present in virtually 100% of 
patient’s PCs. The third recurrent aberration event in MM is represented by distinct 
deletions/gains. The most important and frequent are: the monosomy 13 (45% of the patients)40, 
duplication of the long arm of chromosome 1 (1q gains, 30% to 35% of the patients)41, and deletion 
of chromosome 1p. These two recurrent copy number changes on chromosome 1 are particularly 
relevant being associated with an inferior survival. Different other deletions involving the 6q, 8p, 
12p, 14q, 16q, 17p, or 20p regions have been described in a significant fraction of patients42. All 
these abnormalities have been known for a long time because they are visible on the conventional 
karyotype and on fluorescence in situ hybridization (FISH). Thanks to comparative genomic 
hybridization (CGH) and single nucleotide polymorphism (SNP)–array technologies other important 
chromosomal changes have been revealed, especially homozygotic deletions (Table 2). Taken 
together, all these genomic data have been the scientific proof of evidence of the current model of 
MM pathogenesis (Figure 4). 
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Figure 4. Multiple Myeloma oncogenetic model. Quickly after the oncogenetic event(s), 
differential mutations occur, creating subclones. Secondary events occur later during evolution. 
 
 
Clonal heterogeneity and clonal evolution 
MM has been considered as a clonal malignancy characterized by the secretion of a monoclonal Igs 
or monoclonal free light chains. Although we are able to detect and to describe different clonal 
genomic aberrations (IGH/IGK/IGL hypermutation, IGH translocations, clonal copy number changes 
etc), a more complex situation has been recently revealed. In 2012, three publications reported a 
certain degree of heterogeneity within the dominant clone, by comparing DNA abnormalities 
present at diagnosis and at relapse43-45. Based on SNP array or high-throughput sequencing, all 
three reports demonstrated that the clone observed at relapse could be significantly different from 
the one observed at diagnosis. In some cases, the relapsed clone was characterized by an increased 
genomic complexity, representing a classical clonal model. During this darwinian selection, the 
therapy resistant subclones survive and proliferate, becoming the dominant clone responsible of 
disease relapse3. More strikingly, in some patients, the relapsed clone presented pieces of DNA, 
which were absent at the time of diagnosis. Because ex nihilo creation of DNA is impossible, the 
conclusion of these studies was that minor subclones, undetectable at diagnosis by classical 
methods, were responsible for relapse. The DNA abnormalities defining these subclones were 
mainly supposed to be secondary changes. However, a study focused on the t(4;14), supposed to 
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be a primary driver genetic event, showed that this translocation could be present only in a small 
minor subclone at diagnosis, but be the main clone at relapse, and vice versa46. Thus, the growth of 
subclones is a very early event in oncogenesis, occurring probably shortly after the cell 
transformation (Figure 5). 
 
 
Figure 5. Subclonal evolution. Tumor progression may be characterized by two different evolution models: a 
“linear” evolution with accumulation of genetic events (A) and a “branching” evolution with early separation 
of subclones with different mutations, which undrego differential selection during evolution (B). 
 
Nonetheless, based on combined whole exome sequencing (WES) and single-cell genetic analysis it 
was suggested that up to six different major malignant clones, related by either linear or branching 
evolution, may be present in MM at onset (Figure 5)47. Interesting to note, the study of Melchor 48 
indicated that the activation of the mitogen-activated protein kinase (MAPK) pathway could be the 
result of a convergent phenotype and be explained as a form of parallel evolution that leads 
independent clones, originating from a common ancestor, to acquire activating mutations in the 
same pathway or in genes included in the same pathway48. 
Despite all these progress in MM knowledge, there are still many unanswered questions. First, it is 
still unknown whether several subclones coexisting at the same time in a single patient have 
differential locations. This situation is well described in solid tumors, in fact a branching clonal 
evolution is probably a common feature of various solid49, 50 and hematological tumors (such as 
acute myeloid leukemia)51. However, no data are currently available in MM. Another unresolved 
question is if the subclones selection can solely occur under therapeutic pressure, or does it may 
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occur following a spontaneous pattern during the natural history of the disease1. In the “Darwinian 
model” of intraclonal heterogeneity, multiple clones originate from the same progenitor, each of 
which has the same main feature but also harbors a set of distinctively acquired mutations: the 
prevalence of specific clones (“clonal tiding”) over the others depends on the selective pressure 
determined by the microenvironment (the BM niche) or the treatment. This hypothesis further 
supports the idea that the impact of MM therapy is also related to the underlying biology of the 
disease, and may also explain why high-risk patients have significantly shorter progression-free and 
overall survival than low-risk patients despite their identical response rates3, 52. 
 
 
Multiple myeloma: a single or multiple disease? 
As widely described above, MM represent a very heterogeneous disease and this was confirmed by 
all possible levels of investigation (clinical, cytogenetical, or molecular). Missing a specific common 
driver genomic hit and considering this genomic complexity, different groups investigated the 
existence of MM sub entities. Similarly to other haematological disease, gene expression profiling 
(GEP) has represented the most used approach for these investigations. In particular, global gene 
and miRNA expression and genome-wide DNA profiling have been used alone or as integrated tools 
to investigate the genomic instability underlying the biological and clinical heterogeneity of MM21, 
53, 54. Generally, all GEP studies described the existence of different MM subgroups, and the majority 
of them were associated with one of the recurrent cytogenetic features55-58 (Figure 6). 
For instance, several global miRNA-profiling studies with impact on gene expression, biological 
relevance, and survival have been published, and imply a possible association with myeloma 
pathogenesis and molecular sub-entities in terms of specific chromosomal aberrations or gene 
expression-based high-risk groups59. 
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Figure 6. Distinct molecular types of MM defined by FISH are associated with specific gene 
expression profiles60, 61. 
 
The biological heterogeneity of MM was further confirmed by CGH/SNP-array analyses. Apart from 
the HRD group (which appears also heterogeneous based on the trisomy combinations), some 
other distinct subgroups were identified. Similarly to GEP, all these groups were generally related 
with the most common copy number changes such as monosomies 13 and 14, 1p deletions and 1q 
gains. Whether these subgroups represent different myeloma entities remains to be explored. 
However, it is quite clear that these approaches confirmed the MM heterogeneity and generally 
reproduced the different effect of known recurrent aberrations. 
 
 
Sequencing analyses 
Recently, thanks to novel parallel sequencing technology, we significantly improved our 
understanding of different types of cancers, including MM. In the last years, several studies have 
shown that whole-genome sequencing (WGS) and WES are cost effective means of identifying 
protein-coding mutations. While WGS allows the unguided entire DNA sequencing of an organism’s 
genome, WES is the most efficient way to identify genetic variants in protein-coding genes62. Three 
major papers investigated by NGS techniques the mutational landscape of MM63-65. The first study 
of Chapman et al.63 analysed whole genome and exome sequence data of 38 patients at different 
disease stages (diagnosis, relapse) and indicated that the distribution of mutations was widely 
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variable between patients, confirming the large heterogeneity observed at the clinical or biological 
level. Larger exomes studies confirmed this mutational landscape64, 65 (Figure 7): the high frequency 
of nonsynonymous variants in MM and the progressive increase of non-silent mutations from 
asymptomatic to extramedullary disease (from <10 to almost 60 median mutations across MGUS, 
high-risk sMM, MM, and PCL)66. A further increased mutational load has been observed in myeloma 
cell lines67. When compared with other tumors, MM is in the middle, between low-mutated tumors, 
such as leukemia, and highly mutated carcinogen-induced tumors68. 
Differently from other haematological cancers where NGS approaches allowed to detect a universal 
common driver mutation event (BRAF for Hairy Cell Leukaemia and MYD88 for Waldenstrom 
macroglobulinemia)69, 70, in MM all the three studies failed to detected a specific driver event 
shared by all patients. Few mutations were described as recurrent without exceeding more than 
30% of all patients (i.e NRAS and KRAS)63-65, 71. Several others mutations were observed in a few 
percent of the patients, but 30 genes were found recurrently mutated in at least 5% of the patients. 
Of note, many of these mutations are observed only in subclones, including genes supposed to act 
as drivers (NRAS, KRAS, BRAF, for instance)64, 65 (Figure 7). 
 
 
Figure 7. Landscape of genetic alterations and recurrently mutated genes in multiple myeloma 
in 2 datasets: (A) Lohr et al.65 and (B) Bolli et al.64. 
 
Introduction 
24 
Among the recurrently mutated genes with putative oncongenic role, the most frequent are KRAS, 
NRAS, TP53, BRAF, TRAF3, FAM46C and DIS3, confirming the main involvement of both tirosine 
kinase receptor and NF-kB pathways. Mutations in NRAS, KRAS and TP53 genes are recognized 
markers of advanced disease in MM, and they had been already described as frequent by 
conventional sequencing3; overall, they occur in up to 50% of MM patients if not more.  
 
BRAF mutations in MM 
Genome-wide NGS studies have provided a rationale for molecularly aimed treatment approaches 
by identifying specifically targetable mutations such as those in the RAS/MAPK pathway, which are 
the most prevalent mutations in MM63-65, 72. The BRAF gene maps to chromosome 7 (7q34) and 
encodes a protein belonging to the RAF family of serine/threonine protein kinases, involved in the 
regulation of the MAPK/ERK signaling pathway, that affects cell division, differentiation, and 
secretion. Along with already known NRAS and KRAS mutations, BRAF mutations, recently reported 
to occur in 4-15% of patients63-65, may be of potentially immediate clinical relevance because of the 
availability of effective BRAF inhibitors that are also being investigated in MM treatment73-75. The 
substitution of valine 600 to glutamic acid (V600E) has been reported pathognomonic in B-cell hairy 
cell leukemia69, accounting for about 30%64 to 55%65 of observed BRAF variants.  
 
DIS3 mutations in MM 
DIS3 encodes a highly conserved ribonuclease, which serves as the catalytic component of the 
exosome complex, prominently participating to RNA processing and turnover, and it maps to 
chromosome 13 (13q22.1), that is found deleted in 50% of MM patients. The protein is composed 
of two functional domains: the N-terminal PIN (spanning from exon 1 to exon 4), with endonuclease 
activity, and the RNB (spanning from exon 10 to exon 18) at the C-terminal, with exonuclease 
activity, this the most important for cell physiology. The exosome plays a fundamental role in most 
RNA metabolic pathways. DIS3 is indispensable for survival in vertebrates and its function cannot 
be substituted by other homolog exosome-associated nucleases76. Somatic mutations in DIS3 and 
altered expression have been reported in several cancer types (COSMIC catalogue, Release v71, 
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/)77, 78 and it is recurrently mutated on 
average in 11% of MM patients63, 65, 79, 80. DIS3 mutations in MM prevalently affect the RNB domain. 
Preliminary functional analysis suggested that MM-associated mutations in DIS3 RNB domain 
(inhibiting its exonuclease activity) are indeed synthetically lethal with inactivation of DIS3 
endonucleolytic activity, consequent to the disruption of endoribonucleolytic domain functionality. 
Furthermore, very recently our group demonstrated that DIS3 facilitates the maturation of the 
tumor suppressor let-7 miRNAs by reducing in the cytoplasm the RNA stability of the pluripotency 
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factor LIN28B, an inhibitor of let-7 processing. Through the reduction of mature let-7, DIS3 
enhances the translation of let-7 targets such as MYC and RAS leading to enhanced tumorigenesis81. 
 
FAM46C mutations in MM 
FAM46C recently emerged as a commonly mutated gene in MM (~5-13%)63-65, 71, 79. Although its 
function is still unknown, correlations have been found between the expression of FAM46C and 
that of ribosomal proteins and eukaryotic initiation and elongation factors involved in protein 
translation, prompting for a functional role in the regulation of translation. FAM46C maps to 1p12, 
frequently deleted in MM (more than 20% patients), in most of the cases as part of a larger deleted 
region extending telomerically to the 1p32.3 region, associated with poorer prognosis82. FAM46C 
alterations (either including loss-of-heterozygosity or mutations) were described to be associated 
with impaired overall and progression-free survival83.  
FAM46C appears to be a type I interferon-stimulated gene (ISG) and it encodes a protein that seems 
to silence the replication of viruses and to have a role in both protein translation and as a stability 
factor for mRNA.  
Undoubtedly, recurrent mutations in DIS3 and FAM46C prompted for further investigation of 
altered RNA-processing machinery and protein homeostasis mechanisms in MM. 
 
TP53 mutations in MM 
The tumor suppressor protein p53, encoded by the TP53 gene at chromosome 17p13, mediates the 
response to various stress signals (including DNA damage, oxidative stress, ribonucleotide 
depletion, and deregulated oncogene expression), many of which are encountered during tumor 
development and malignant progression84. Loss of p53 function, due to TP53 deletions and/or 
mutations or by defects in the signaling pathways upstream or downstream of p53, is associated 
with oncogenesis, cancer progression and drug resistance. TP53 is mutated in about half of human 
cancers, and the prevalence of gene mutations greatly varies between different tumor types. 
Recently, WES analyses in MM64, 65, 71, 79, albeit reporting slightly higher mutational frequencies 
(probably for the extension of the analysis to the entire coding sequence and the greater 
sensitivity), confirmed the findings of the early studies85-88: TP53 mutations are relatively rare at 
presentation (mutation prevalence ranging from 0% to 9.7% in representative MM patients’ 
cohorts). The frequency of mutations increases with disease stage, reaching 25-30% in PCL89, 90 and 
80% in HMCLs91. 
A strong association has been described between TP53 mutation and del(17p)92. Deletions, 
predominantly monoallelic, of chromosome 17p13 region containing the TP53 gene locus occur in 
about 10% of untreated MM cases40, 93, 94; the incidence rate reported in PCL ranges from 35% to 
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75%90, 95. 17p13 deletion confers a very negative effect on survival96, displaying the most powerful 
cutoff for predicting survival if the deletion is carried by more than 50% of malignant PCs97. Finally, 
a recent study identiﬁed TP53 as the critical gene of 17p13 deletion in MM98. 
 
 
The liquid biopsy 
Cancer treatment relies on the availability of accurate molecular profiles of individual tumors, 
which are currently determined by genetic analysis of DNA samples extracted from the neoplastic 
tissue. Tumor genotyping of mature B-cell tumors lacking a leukemic phase has so far relied on the 
analysis of the diagnostic tissue biopsy; in fact, MM characterization currently depends on BM 
aspirates for mutational analysis. However, multiregional sequencing of cancers showed that this 
approach might not capture the putative spatial and genetic heterogeneity of this multi-focal 
disease because the diagnostic tissue biopsy might be subjected to a selection bias resulting from 
spatial heterogeneity and, therefore, might not be representative of the entire tumor genetics. 
Indeed, different areas of the same tumor may show different genetic profiles (i.e. intratumoral 
heterogeneity). A biopsy from one part of a tumor may miss mutations occurring in subclones, 
including clinically relevant genetic biomarkers for treatment tailoring or anticipation of 
resistance99.  
In particullary, MM genotyping has so far relied on the analysis of purified PCs from the BM aspirate, 
which may fail in capturing the postulated spatial heterogeneity of the disease and imposes 
technical hurdles that are limiting its transfer in the routine and clinical grade diagnostic laboratory. 
In addition, longitudinal monitoring of disease molecular markers may be limited by patient 
discomfort caused by repeated BM samplings during disease course. Data produced in solid cancers 
indicate that circulating tumor DNA into the peripheral blood (PB) can be used as source of tumor 
DNA to provide information about tumor mass, residual disease and tumor genotype, with obvious 
advantages in terms of accessibility.  
Cell-free DNA (cfDNA) fragments are shed into the bloodstream by cells undergoing apoptosis 
(Figure 8). Since these processes occur ubiquitously in the body, the blood plasma of healthy 
individuals by default contains circulating cfDNA at steady-state levels and primarily derived from 
hematopoietic cells100. In cancer patients, cfDNA also contains, besides cfDNA derived from 
nonmalignant cells, a fraction of circulating tumor DNA (ctDNA) as tumor cells also shed DNA into 
the circulation101.  
Information acquired from a single biopsy provides a spatially and temporally limited snapshot of 
a tumour and might fail to reflect its heterogeneity. Tumour cells release ctDNA into the blood, but 
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the majority of circulating DNA is often not of cancerous origin, and detection of cancer-associated 
alleles in the blood has long been impossible to achieve. 
 
 
Figure 8. Release and extraction of cfDNA from the blood. cfDNA is released from healthy, 
inflamed or diseased (cancerous) tissue from cells undergoing apoptosis or necrosis102.  
 
Recent advances in the sensitivity and accuracy of DNA analysis have allowed for genotyping of 
cfDNA for the identification of somatic cancer gene mutations103. The capability to detect and 
quantify tumor mutations has being proven effective in tracking tumor dynamics in real time as 
well as serving as a “liquid biopsy” that can be used for a variety of clinical and investigational 
applications not previously possible. Circulating DNA is representative of the entire tumor 
heterogeneity, thus allowing to bypass the bias imposed by BM biopsies in the reconstruction of 
the entire cancer clonal architecture, and to identify resistant clones that are dormant in non-
accessible tumor sites. Accessing the blood stream has also clear sampling advantages in the serial 
monitoring of treatment emergent resistant mutations in real time103.  
In recent months, the first promising studies on the circulating ctDNA in MM patients have 
appeared, tracking the clonotypic V(D)J rearrangement as disease fingerprint104, or genotyping a 
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highly restricted set of cancer genes that were not specifically addressed to resolve typical MM 
mutational landscape105-107. 
Conversely, these studies have been the proof that cfDNA can be also used as a “liquid biopsy” to 
gain a representative snapshot of the underlying tumor genetics for diagnostic or prognostic 
purposes, to inform treatment decision, to track clonal evolution-driven resistance upon treatment, 
and in the end, to inform patient management in real time, still lacking in many mature B-cell 
tumors and, in particular, in MM. 
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In the last decade, important advances in molecular cytogenetics and global genomic studies 
brought a significant progress in the comprehension of MM pathogenesis. By combining global GEP 
and FISH analyses, our laboratory and other groups have contributed to define the transcriptional 
profiles associated with MGUS, MM and PCL, and those related to the major molecular subclasses 
of MM53, 61, 108, 109. Furthermore, this integrated genomics approach was developed to detect allelic 
imbalances in MM110, thus revealing a wide gene dosage effect. 
Recently, our group performed genome-wide studies, along with global gene and miRNA expression 
profiling analyses on a prospective series of pPCL at diagnosis, enrolled in an Italian multicenter 
clinical trial, thus revealing genomic and miRNA/gene expression patterns distinguishing pPCL from 
MM, and specific molecular signatures associated with clinical outcome95, 111, 112. More recently, a 
whole exome sequencing study has been performed on cohort fraction of the same pPCL cases, 
thus evidencing a heterogeneous mutational pattern in pPCL, involving several pathways with a 
central role in the pathogenesis of PC dyscrasia89. 
The first aim of this project was the evaluation of the incidence of mutations in MM driver genes 
(KRAS, NRAS, TP53, BRAF, FAM46C and DIS3), as suggested by several recently previous massive 
DNA sequencing studies63-65, in a large and representative cohort of patients at different stages of 
PC dyscrasia. DNA sequencing of gene mutation hot-spots was performed by means of deep NGS 
on Roche Junior 454 platform, able to detect also mutations present at subclonal level and 
undetectable by conventional sequencing. Obtained data have been subsequently validated by 
means of Sanger sequencing or independent 454 re-sequencing. The research activity also aimed 
to identify possible correlations between the presence of driver mutations and the main MM 
genetic lesions, namely IGH translocations, hyperdiploidy, deletions of chromosomes 1p, 13q and 
17p, and 1q gain; as well as the occurrence of mutations in major and minor subclones. Mutational 
patterns were also related with gene and miRNA expression profiles, available for the great majority 
of patients, to understand better their role in the biology of the disease and clinical outcome. The 
integration of mutational, genomic and transcriptomic data should hopefully allow to better 
stratifying MM patients at diagnosis. 
Additionally, to investigate the longitudinal state of driver gene mutations, we analyzed a small set 
of MM patients for whom BM specimens were collected at two different time points, to gain further 
insight on the evolution of MM clonal structure. We also performed deep sequencing of cDNA of 
the mutated cases to verify if the mutations detected on genomic DNA are also expressed at 
transcriptomic level.  
 
The second aim of the project was based on the observation that circulating DNA is a powerful non-
invasive biomarker currently used to identify somatic cancer gene mutations, also due to its 
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representativeness of the entire tumor heterogeneity. In MM, this peculiarity would allow to 
bypass the bias imposed by BM biopsies in the reconstruction of the entire cancer clonal 
architecture, and to identify resistant clones that are dormant in not accessible tumor sites. 
Our working hypothesis was that cfDNA represents an accessible source of tumor DNA for the 
sensitive identification of genetic biomarkers that refine the diagnostic workup, stratify prognosis 
and inform treatment decision in MM. The project aimed at comprehensively validating the “liquid 
biopsy” as a diagnostic tool to inform in real time MM diagnosis, prognostication and treatment 
monitoring. The task was designed as a retrospective observational study by the analysis of a 
consecutive series of MM patients, whose plasma cfDNA, tumor and germline genomic DNA (gDNA) 
were analysed, by means of targeted ultra-deep-NGS. An updated targeted resequencing gene 
panel including the coding exons and splice sites of genes that are recurrently mutated in MM had 
been specifically designed for this project in collaboration with Prof. Davide Rossi at the Institute of 
Oncology Research (IOR) in Bellinzona (CH). Circulating tumor DNA analysis could represent a less 
expensive and sustainable approach to determine MM patients’ subgroups that could obtain the 
greatest benefit with specific chemoimmunotherapy regimens. 
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Patients  
Pathological BM specimens from 132 patients with newly diagnosed MM, 24 cases of pPCL at onset 
and 11 cases of sPCL, admitted from July 2001 to April 2014, were obtained during standard diagnostic 
procedures after the patients had given their informed consent according to institutional guidelines 
(clearance from Ethic Committee, Fondazione Ospedale Maggiore di Milano). Seventy-nine patients 
were males; median age was 66 years (range: 42–85). MM and PCL were diagnosed based on the 
previously described criteria15, 17, 113. Many of the patients included in this study have been described in 
our previous reports53, 108, 112, and 16 of the 24 pPCL patients were participants in a multicentre clinical 
trial (RV-PCL-PI-350, EudraCT No. 2008-003246-28)114, aimed at evaluating safety and anti-tumor 
activity of combined lenalidomide and dexamethasone as ﬁrst-line treatment115. 
One hundred patients had an IgG protein monoclonal component; 34 IgA; one IgG/ IgA; and one IgM 
protein; 101 cases had the light chain κ; 63 λ; two λ+κ. Twenty-five MM cases were in stage IA, 58 IIA/B 
and 49 IIIA/B. The diagnoses were made by means of conventional morphology and immunophenotype 
analyses and the patients were clinically staged according to Durie and Salmon criteria [Durie BG, 
Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass 
with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36:842-854]. No 
conventional cytogenetic (G-banding) analyses were available. 
For the study on cfDNA a total of 28 patients were recruited from September 2016 to May 2017 in 
Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico (Milan, Italy) and in Oncology Institute of 
Southern Switzerland (Bellinzona, Switzerland) if they fulfilled the inclusion criteria: (1) male or female 
adults; (2) diagnosis of MM or MGUS after pathological revision; (3) evidence of signed informed 
consent. Patients provided informed consent in accordance with local institutional review board 
requirements and the Declaration of Helsinki. The clinical prognostic system for the patients were, 
according to International Staging System (ISS), based on b2-microglobulin and albumin, with stage I 
representing limited disease, stage II intermediate, and stage III the most unfavorable disease116, 117. 
The following biological material was collected: (1) cfDNA isolated from plasma, (2) tumor gDNA from 
the CD138+ purified PCs from BM aspiration and (3) normal germline gDNA extracted from PB 
granulocytes.  
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Sample preparation and FISH analyses 
BM specimens were collected from patients at the time of diagnosis; 19 cases (14 with MM and two 
with pPCL at onset and relapse; two with MM at onset and at the time of leukemic transformation; and 
one at early and relapsed leukemic phase) were re-sampled at relapse/MM leukemic transformation, 
with a median time interval between the two samplings of 30 months. 
Tumor gDNA was isolated from PCs puriﬁed from the BM samples using CD138 immunomagnetic 
microbeads as previously described61, 118. The purity of the selected PC populations was assessed by 
means of morphology and ﬂow cytometry, and was >90% in all cases.  
PB granulocytes were separated by Ficoll gradient density centrifugation as a source of normal germline 
gDNA. 
All samples were characterized by FISH for the main genomic aberrations: IGH translocations 
(t(4;14)(p16.3;q32); t(11;14)(q13;q32); t(14;16)(q32;q23); t(6;14)(p21;q32) and t(14;20)(q32;q11)), 
del(13)(q14), del(17)(p13), hyperdiploidy, 1p33 (CDKN2C) loss and 1q21.3 (CKS1B) gain. FISH analysis 
for the detection of 13q14 and 17p13 deletions, hyperdiploidy, t(4;14), t(11;14), t(14;16), t(14;20) and 
aberrations of chromosome 1 were performed using the protocol provided by the manufacturer of the 
multicolor probes LSI D13S19/LSI 13q34, LSI TP53/CEP17, LSI D5S23/D5S721/CEP9/CEP15, LSI 
IGH/FGFR3, LSI IGH/CCND1 (XT), LSI IGH/MAF (Vysis Inc., DownersGrove,IL), IGH/MAFB Plus and 
CKS1B/CDKN2C (P18) (Cytocell Ltd, Cambridge, UK), respectively. To investigated the t(6;14), we 
performed dual-color FISH using the 973N23 clone (specific for CCND3) in combination with PAC clone 
998D24 (specific for IGH locus). The clones were selected by browsing the University of California, Santa 
Cruz (Santa Cruz, CA) Genome Database (http://genome.ucsc.edu/)110. 
The cut-off levels considered were 10% for fusion or break-apart probes and 20% for numerical 
abnormalities, as recommended by the European Myeloma Network (EMN). 
 
 
DNA extraction and quantification 
Genomic DNA was extracted using Wizard genomic puriﬁcation DNA kit (Promega Corporation, 
Madison, WI, USA) according to the instructions of the manufacturer and eluted in TE. The 
concentration of DNA extracted was assessed by spectrophotometric quantification with Nanodrop 
(Thermo Fisher Scientific Inc, Waltham, MA, USA) and by Quant-iT™ PicoGreen dsDNA Assay kit 
(ThermoFisher Scientific). All genomic DNA was stored at −20°C until use. 
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Isolation and analysis of plasma cfDNA 
PB (20 ml) was collected in Cell-Free DNA BCT tubes that allow obtaining stable cfDNA samples while 
preventing gDNA contamination that may occur due to nucleated cell disruption during sample storage, 
thus avoiding pre-analytical issues affecting cfDNA genotyping. PB was centrifuged at 820 g for 10 min 
to separate plasma from cells. Plasma was then further centrifuged at 20000 g for 10 min to pellet and 
remove any remaining cells and stored at -80°C until DNA extraction. CfDNA was extracted from 1-3 ml 
aliquots of plasma (to allow the recovery of enough genomic equivalents of DNA to reach a genotyping 
sensitivity of 10-3) using the QIAamp circulating nucleic acid kit (Qiagen) and quantized using Quant-iT™ 
PicoGreen dsDNA Assay kit (ThermoFisher Scientific). Contamination of plasma cfDNA from gDNA 
released by blood nucleated cell disruption was ruled out by checking, through the Bioanalyzer (Agilent 
Technologies) instrument, the size of the DNA extracted from plasma.  
 
 
Mutation analyses by the 454 GS Junior System 
After DNA extraction and quantification, all samples were subjected to polymerase chain reaction (PCR) 
amplification and deep sequencing by the 454 GS Junior System (454 Life Sciences, Branford, CT, and 
Roche Applied Sciences, Indianapolis, IN). The 454 GS Junior technology is derived from the 
technological convergence of emulsion PCR and pyrosequencing. Genomic DNA was amplified using 
special fusions primers containing genome-specific sequences (reported in Table 3 for each gene) 
(Primer-BLAST at http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome), 
and a universal tails at the 5’ end to allow the addition of specific MIDs (multiplex identifier sequences 
used to differentiate samples being run together on the same plate) in a second amplification step 
(Figure 9).  
PCR reactions were run in 25μl reaction volumes, containing 10 mmols dNTPs, 10 μM of each primer, 
2.5 μl PCR buffer, 12.5 ng DNA, and 0.25 μl of FastStart High Fidelity Polymerase (Roche). Amplicon 
library A and B sequencing adapters and multiplex identifier (MID) tags were then added to both tails 
of amplicons by a second amplification step. PCR conditions were as follows: in the first amplification 
step, denaturating step at 94°C for 5 min followed by 25 cycles at 94°C (30 sec. per cycle), annealing 
step at 53°C (for DIS3 exon 1), 57°C (for BRAF, NRAS, KRAS and DIS3 exons 10, 11 and 17), at 58°C (for 
the remaining exons of DIS3, FAM46C and TP53) (30 sec. per cycle), and extension at 72°C (45 sec. per 
cycle), followed by a final 7 min extension at 72°C. In the second amplification step, denaturating step 
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at 94°C for 5 min followed by 25 cycles at 94°C (20 sec. per cycle), annealing step at 55°C (20 sec. per 
cycle), and extension at 72°C (45 sec. per cycle), followed by a final 10 min. extension at 72°C. 
PCR products were visualized on agarose gel, purified using Ampure-XPDNA-binding paramagnetic 
beads (Agencourt Bioscience Corp., Beckman Coulter S.p.A, Milan, Italy), and quantified in 96-well 
format using picogreen dye (Life Technologies, Carlsbad, California) and the Victor X2 (Perkin Elmer, 
Waltham, Massachusetts) fluorometer. 
Samples were then diluted to an approximate concentration of 1×109 molecules/μL and pooled at 
equimolar concentrations to create a highly multiplexed amplicon library. After pooling, the library was 
further diluted to 106 molecules/µl and subjected to emulsion PCR (emPCR) at a ratio of 0.8 molecules 
per bead using the 454 GS Junior Titanium Series Lib-A emPCR Kit (Roche Diagnostics), according to the 
manufacturer’s protocols. Following emPCR, the captured beads with bound DNA were enriched with 
a second DNA capture mechanism to separate out beads with and without bound emPCR products. 
A mean of 500.000 enriched beads was used for massively parallel pyrosequencing in a Titanium 
PicoTiterPlate® (PTP) with Titanium reagents (Roche Diagnostics), on the GS Junior instrument, 
according to the 454 GS Junior Titanium Series Amplicon Library Preparation Method Manual (available 
online: www.454.com). The obtained sequencing reads were mapped to the reference sequence 
(indicated in table Primer) (RefSeq GRCh37.p13) and analyzed by the Amplicon Variant Analyzer (AVA) 
software version 3.0 (454 Life Sciences) to establish the mutant allele frequency.  
The presence of each obtained non-synonymous variant was verified in an independent PCR product, 
analyzed by conventional sequencing whenever the sensitivity of the Sanger’s method was consistent 
with the variant allele frequency (VAF). NGS analysis was repeated (run median depth of 
coverage=200x) in cases of mutations in less than 10% of the DNA molecules to differentiate real 
mutations from low-level errors introduced during PCR ampliﬁcation and sequencing. To exclude 
germline variants we sequenced the matched normal DNA, when available, or consulted the Human 
dbSNP Database at NCBI (Build 142) (http://www.ncbi.nlm.nih.gov/snp) and removed from the analysis 
changes present in germline samples or with a corresponding rs entry (unless the same variant was also 
included in NCBI ClinVar database). For TP53 mutatios the International Agency for Research on Cancer 
(IARC) Database (http://www-p53.iarc.fr) was consulted to obtain informations about the functional 
relevance of the detected mutations. Specifically, a TP53 mutant was classified as “non-functional” if 
the median of its transcriptional activities measured in reporter assays on eight different promoters 
containing TP53-binding sequences was lower than 20% compared to the wild type protein. We 
acquired additional information about the functional relevance of the detected single-nucleotide 
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variants (SNVs) using five tools which predicts possible impact of amino acid substitutions on the 
structure and function of human proteins using straightforward physical and evolutionary comparative 
considerations. The functional predictors used were Polyphen2 
(http://genetics.bwh.harvard.edu/pph2/), Mutation Taster (http://www.mutationtaster.org/), 
Mutation Assessor (http://mutationassessor.org/), SIFT (http://sift.jcvi.org/) and LRT 
(http://www.genetics.wustl.edu/jflab/lrt_query.html). 
 
Table 3. Genome-specific primers for amplicon library preparation. Pubblished primers for BRAF 119, 
NRAS 113 and KRAS 120. 
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Figure 9. Schematic representation of the PCR reaction components for the preparation of a two 
step Universal Tailed Amplicon Library. A) First step, targeting the template-specific sequences and 
adding the universal tail. B) Second step, targeting the universal tail and adding the 454 Sequencing 
System primers and MIDs. 
 
 
Validation of variants at transcriptomic level 
To verify the occurrence of the obtained variants at transcriptomic level, total RNA of mutated samples 
was converted to cDNA using M-MLV reverse transcriptase (Invitrogen) and random hexamers, and 
subjected to deep sequencing of the exon harboring the variant/s detected on genomic DNA. 
Sequence-specific exon PCR primers were designed in the Primer 3 program 
(http://frodo.wi.mit.edu/primer3/) as reported in Table 4. 
 
Table 4. Sequence-specific exonic PCR primers for validation of variants. 
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Library design and CAPP-seq approach for ultra-deep NGS by Illumina MiSeq 
A targeted resequencing gene panel, including coding exons and splice sites of 14 genes that are 
recurrently mutated in MM patients was specifically designed for this project (target region of 30989bp: 
BRAF, CCND1, CYLD, DIS3, EGR1, FAM46C, IRF4, KRAS, NRAS, PRDM1, SP140, TP53, TRAF3, ZNF462) in 
collaboration with Prof. Davide Rossi at IOR in Bellinzona (CH). Inclusion criteria of gene panel design 
were based on publicly available sequencing data from three distinct datasets64, 65, 121 and were as 
follows: (i) genes that were recurrently mutated in ≥ 3% of MM tumors; (ii) genes that were cross-
validated in at least two of the considered genomic datasets. An in silico validation of the designed gene 
panel in the three aforementioned patients cohorts resulted in the recovery of at least one clonal 
mutation in 68% (95% confidence interval [CI]: 58% to 76%) of MM cases (Figure 10). 
 
 
Figure 10. (A) Heatmap showing MM patients (in total 412 cases) of the three works64, 65, 121 on which 
the study design was based; in red mutated cases. (B) Word clouds (created on 
http://www.wordle.net) representing the most mutated genes chosen for the panel. The percentage 
of the gene’s prevalence generally in the distinct datases64, 65, 121 is shown by gene name size. 
 
The gene panel was analyzed in plasma cfDNA and in normal gDNA from the paired granulocytes, as 
source of germline material, for comparative purposes to filter out polymorphisms. The gDNA from the 
paired CD138+ purified PCs from BM aspiration was also investigated in the same cases to assess the 
accuracy of plasma ctDNA genotyping. Tumor and germline gDNA (median 400 ng) were sheared 
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through sonication before library construction to obtain 150-bp fragments. Plasma cfDNA, which is 
naturally fragmented, was used (median 59 ng) for library construction without additional 
fragmentation. Targeted ultra-deep-NGS was performed on plasma cfDNA, tumor and germline gDNA 
by using CAncer Personalized Profiling by deep Sequencing (CAPP-Seq) approach (Figure 11), which has 
been validated for plasma ctDNA genotyping122. The NGS libraries were constructed using the KAPA 
Library Preparation Kit (Kapa Biosystems) and hybrid selection was performed with the custom SeqCap 
EZ Choice Library (Roche NimbleGen). The manufacturer's protocols were modified as previously 
reported 122. Multiplexed libraries were sequenced using 300-bp paired-end runs on an Illumina MiSeq 
sequencer. Each run included 24 multiplexed samples in order to allow >2000x coverage in >80% of the 
target region. 
 
 
Figure 11. An overview of the workflow of CAPP-Seq and hybridization capture protocol. 
 
 
Bioinformatic pipeline for variant calling and statistical analysis 
Mutation calling in plasma cfDNA was performed separately and in blind from mutation calling in tumor 
gDNA from purified PCs. We deduped FASTQ sequencing reads by utilizing FastUniq v1.1. The deduped 
FASTQ sequencing reads were locally aligned to the hg19 version of the human genome using BWA 
v.0.6.2, and sorted, indexed and assembled into a mpileup file using SAMtools v.1. The aligned reads 
were processed with mpileup. Single nucleotide variations and indels were called in plasma cfDNA vs 
normal gDNA, and tumor gDNA vs normal gDNA, respectively, by using the somatic function of 
VarScan2. The variant called by VarScan 2 were annotated by using SeattleSeq Annotation 138. Variants 
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annotated as SNPs, intronic variants mapping >2 bp before the start or after the end of coding exons, 
and synonymous variants were filtered out. To filter out variants below the base-pair resolution 
background frequencies, the Fisher's exact test was used to test whether the variant frequency called 
by VarScan 2 in cfDNA or tumor gDNA, respectively, was significantly higher from that called in the 
corresponding paired germline gDNA, after adjusting for multiple comparison by Bonferroni test 
(Bonferroni-adjusted P=4.03252e-7). To further filter out systemic sequencing errors, a database 
containing all background allele frequencies in all the specimens analyzed was assembled. Based on 
the assumption that all background allele fractions follow a normal distribution, a Z-test was employed 
to test whether a given variant differs significantly in its frequency from typical DNA background at the 
same position in all the other DNA samples, after adjusting for multiple comparison by Bonferroni. 
Variants that did not pass this filter were not further considered. Variant allele frequencies for the 
resulting candidate mutations and the background error rate were visualized using IGV.  
The sensitivity and specificity of plasma cfDNA genotyping were calculated in comparison with tumor 
gDNA genotyping as the gold standard. The analyses were performed with the Statistical Package for 
the Social Sciences (SPSS) software (Chicago, IL) and with R statistical package (http://www.r-
project.org). 
For analyses of correlation were used Pearson correlation’s method and Mann-Whitney test.  
 
 
Gene expression profiling and statistical analysis 
In order to identify the transcriptional profiles related to the mutations in primary tumors, we used 
microarray technology to investigate GEP of a large number of the samples analyzed by NGS. Total RNA 
was puriﬁed using the RNeasy® Total RNA Isolation Kit (Qiagen, Valencia, CA). Preparation of DNA 
single-stranded sense target, hybridization to GeneChip® Gene 1.0 ST arrays (Affymetrix, Santa Clara, 
CA) and scanning of the arrays (7G Scanner, Affymetrix) were performed according to the 
manufacturer’s protocols112. The raw intensity expression values were processed by Robust Multi-array 
Average (RMA) procedure123, with the re-annotated Chip Deﬁnition Files from BrainArray libraries 
version 18.0.0124, available at http://brainarray.mbni.med.umich.edu. Supervised analyses were 
performed using Signiﬁcant Analysis of Microarrays software (SAM version 4.00; Excel front-end 
publicly available at http://www-stat.stanford.edu/tibs/SAM/index.html)108, 125. The cutoff point for 
statistical signiﬁcance was determined by tuning the Δ parameter on the false discovery rate (FDR) and 
controlling the q-value of the selected probes (q-value=0). Differentially expressed genes were also 
Materials and Methods 
42 
evaluated at the highest stringency level (median FDR 0%, 90th percentile FDR = 0). The functional 
annotation analysis on the selected lists was performed by means of DAVID 6.7 
(http://david.abcc.ncifcrf.gov/) and the ToppFun option in ToppGene Suite 
(https://toppgene.cchmc.org/) tools, using the default parameters126. 
The principal component analysis (PCA) of the samples was performed by singular value decomposition 
of the considered data expression matrix using the prcomp function in the stats package, and the results 
were visualized using the plot3d function in the rgl package for R software.  
The GEP data have been deposited in the NCBI Gene Expression Omnibus database (GEO; http//www. 
ncbi.nlm.nih.gov/geo; accession No. GSE66293).  
All contingency analyses were performed by Fisher’s exact test. A P value <0.05 was considered 
signiﬁcant for all statistical calculations. A P-value cut-off of 0.05 and FDR Benjamini and Hochberg 
correction method were applied to all the annotation terms in the default parameter set, and those 
with a q-value <0.05 were defined as significantly enriched.  
  
 
 
 
 
 
 
Results 
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Multiple myeloma and plasma cell leukemia samples  
To estimate the frequency of KRAS, NRAS, BRAF, DIS3, FAM46C and TP53 mutations in PC dyscrasia, we 
investigated by NGS a retrospective cohort of 132 cases with MM at onset and 24 patients with pPCL, 
11 with sPCL (see Materials and Methods for patient populations). In order to gain further insights into 
the longitudinal status of mutations, we analyzed specimens taken from 19 patients at two different 
times: 14 with MM and two with pPCL at onset and relapse; two with MM at onset and at the time of 
leukemic transformation; and one at early and relapsed leukemic phase. Pathological samples from all 
patients were characterized by FISH for the presence of the main molecular alterations occurring in 
MM (Table 5). The cohort analyzed was the same for all sequenced genes, except for three cases (2 
MM and 1 pPCL) not longer available for DIS3, 4 cases (another MM in addition) for TP53 and 5 cases 
for FAM46C (another MM too). 
 
Specifically, we performed deep sequencing of the following mutational hot-spots: exons 11 and 15 in 
BRAF, exons 2-3 in NRAS and exons 2-4 in KRAS (Cosmic Release v70, at 
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/); the two functional domains of DIS3, PIN 
(exons 1-4) and RNB (exons 10-18) domains; exon 2 in FAM46C and exons 4-9 in TP53. These mutational 
hotspots contained almost 98% of mutations, identified in the main previously published whole 
genome and exome sequencing studies in MM65 64 79. The median depth of coverage was ~200x (range 
100-1000x). 
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Table 5. Clinical details of the 167 patients analyzed by the 454 GS Junior System. ΔThe Durie clinical 
staging system was adopted; ‡ND: newly diagnosed, RR: relapsed/refractory; †Paraprotein; *del(13), 
del(17), 1p loss and 1q gain were determined by FISH. °HD= presence of the hyperdiploid status 
based on FISH evaluation criteria; na: not applicable. 
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Assessment of mutations in PC dyscrasias  
After exclusion of intronic, synonymous and germline variants, deep sequencing revealed different 
coding somatic mutations as follows: 8 in BRAF, 13 in NRAS, 23 in KRAS, 30 in DIS3, 24 in FAM46C, 
14 in TP53 (Table 6 and Figure 12). The presence of each non-synonymous SNV was verified in an 
independent PCR product, analyzed by conventional sequencing whenever the sensitivity of the 
Sanger’s method (i.e. about 10% in our experimental conditions) was consistent with the variant 
allele frequency VAF, or by an additional and ultra-deep pyrosequencing run (median depth of 
coverage=1110x) in case of variants at low allele frequency. 
The high sensitivity of the method allowed mutation detection even at a very low variant allele 
frequency. In fact, a considerable proportion of patients presented with a small mutation load. 
 
BRAF and RAS (NRAS-KRAS) 
Eight distinct single nucleotide variations in BRAF were detected in 20 out of 167 (12%) analyzed 
patients. All of the identified mutations were missense substitutions (Table 6) and the VAFs ranged 
from 0.86% to 70.7% of total reads per sample. Mutations were detected in 10.6% of the patients 
with MM at onset (14/132), 20.8% of pPCLs (5/24) and 9.1% of sPCLs (1/11) and as the whole in the 
12% (20/167) of the cases. Five of these patients (four with MM and one with pPCL) carried a 
mutation whose VAF was below the Sanger detection limit. The variants mainly targeted exon 15 
(17/20, 85%) (Figure 12A). The most frequent mutation V600E was found in seven cases; the 
mutantion G469Awas found in three cases, E586K and G596R substitutions are detected in only 
one sample The most frequently mutated residue in our patients was at D594: with D594N in four 
cases, D594G in three, and D594E in one. 
In order to obtain a more complete picture of MEK/ERK signalling activation in MM, we also 
investigated the entire dataset for mutations in NRAS and KRAS, encoding two GTPases that are 
known for long time to be involved in myelomagenesis64, 65, 127, 128. Sequencing of the mutation hot-
spots of NRAS (exons 2 and 3) and KRAS (exons 2, 3 and 4) revealed, respectively, the occurrence 
of mutations in 23.9% (40/167) and 29.3% (49/167) of the cases. As a whole, NRAS and KRAS 
mutations were detected in 55.3% of MM cases, 20.8% of pPCL, and 54.5% of sPCL. In particular, 
NRAS mutations were found in 26.5% of the MMs at onset, 4.2% of the pPCLs, and 36.4% of the 
sPCLs (P = 0.008) (Table 6). In line with previous studies (particularly in MM), virtually all of the 
identified mutations affected hot-spot codons 61 (36/50, 72%), 13 (5/50, 10%) and 12 (3/50, 6.5%). 
KRAS mutations were detected in 32.6% of the MMs at onset, 16.7% of the pPCLs, and 18.2% of the 
sPCLs; the most frequently targeted residues were Gly12 and Gln61, followed by Gly13 and other 
codons in exons 2, 3, and 4, each mutated in one or two cases (Table 6). 
 
  
Table 6. Summary of non-synonymous variants identified by NGS in BRAF-NRAS-KRAS-DIS3-FAM46C-TP53 genes. *Reference number in bibliography. 
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DIS3 
Deep sequencing of DIS3 revealed 30 different coding somatic mutations globally targeting 27 genic 
positions (Table 6). At DNA level, 27 out of 30 variants (90%) were SNVs, all resulting in missense 
mutations but one (73355968C>T, M1_V16del), which replaces one base within the first coding 
ATG, thus relocating the translation start site 16 codons downstream without altering the reading 
frame. The remaining three variants (10%) were indels: two involved a single different nucleotide 
causing a frameshift, while the other was a 27bp-deletion resulting in an in-frame deletion of nine 
amino acids (L48_A56del). Nonsense mutations were not observed. 
DIS3 mutations globally affected 33 patients (33/164, 20.1%): 24 MMs at diagnosis (24/130, 18.5%), 
six primary PCLs (6/24, 25%), and three secondary PCLs (3/10, 30%).Twenty out of 30 mutations 
(70%) affected the RNB domain, while only eight variants (8/30, 26.7%) were located in the PIN 
domain. The remaining SNV mapped in a region just downstream of the RNB domain. 
Overall, the most affected residue was the arginine at position 780 (R780), replaced by a lysine or 
by a threonine in three and two cases, respectively (Figure 12B). The arginine at position 780 was 
found involved in RNA binding function129. The second most affected residue in our dataset was the 
aspartic acid at position 488 (D488), involved in magnesium ion binding at the active site129. This 
residue was mutated in four cases, all carrying the D488N substitution, which also represents the 
globally most frequent variant in our series. Notably, two missense variants involving D487 residue 
were detected in our dataset: D487V and D487H, each in one patient. Other recurrently mutated 
positions in our series were T93, H764, F775, R789 and R820, each targeted in two samples by the 
same substitution, except for H764 (reported to be involved in RNA binding129) showing different 
amino acid changes. The 17 remaining genic positions were found privately mutated in our cohort.  
Notably, four patients carried multiple DIS3 mutations; only in two of these cases (MM-340 and 
PCL-042) two variants were both at high allele frequency, while in the remaining samples only one 
of the mutations was above the detection limit of Sanger method, accompanied by other variants 
at low allele frequency. In particular, PCL-042 harbored the variants R780K and E626K, both in the 
RNB domain, in 46% and 33% of reads, respectively, and MM-340 carried a nine amino acid in-
frame deletion in the PIN domain (L48_A56del) and a missense substitution in the RNB domain 
(A751D) in 55% and 46% of reads, respectively.  
Beyond the aforementioned R780 and D487 residues, whose importance for the catalytic activity 
of the protein has been functionally proven, a potential detrimental effect on DIS3 nucleolytic 
activity can be suggested also for many of the other mutations we identified here, on the basis of 
their recurrence (as described above), and/or the high conservation of affected amino acid 
residues, and/or the functional predictions returned by different algorithms. In fact, from the 
alignment of human DIS3 protein sequence to mouse and yeast paralogs and to E.coli RNases II and 
Results 
52 
R sequences, we found that 13 of the 24 genic positions targeted by mutations resulting in amino 
acid substitutions or in-frame deletions in our primary patients encoded amino acid residues 
conserved in all the analyzed species.  
 
FAM46C 
We identified 24 tumor-specific mutations (Table 6) affecting 18/162 (11%) MM-pPCL-sPCL 
patients. Of these 24 mutations, 13 (54%) were single nucleotide variations (SNVs), all but one 
(Y291*) of which resulting in missense mutations, while the remaining 11 mutations (46%) were 
indels, six of which causing a frameshift. Globally, the predominantly inactivating nature of these 
identified alterations is consistent with the putative tumor suppressor role of FAM46C in MM.  
It would appear that the FAM46C coding sequence is almost entirely altered by mutations, with the 
exception of small portions, especially in the N-terminal region. In fact, based on the recurrence of 
affected codons, it is difficult to identify mutational hotspots: only 20 out of the 84 residues are 
targeted by mutations in more than one patient (at most four in codon Y291), while the remainder 
are exclusively mutated (Figure 12C). 
Concomitant FAM46C mutations occurred in four MM patients of our series, three of whom 
harboured two or more variants at high variant allele frequency. Notably, MM-049 showed four 
nucleotide deletions, three of which [117623773_11762377 9del(7), 
117623783_117623801del(19) and 117623805delG] were carried by the same allele at an identical 
VAF (41.01%), and should generally result in the alteration S302_R312delinsTK. 
The prevalence of FAM46C mutations (11.7%) identified in our newly diagnosed MM cohort was 
similar to that described in previous studies63-65, but higher than the one more recently reported by 
Walker et al (2015). FAM46C mutations also occurred in extramedullary myeloma; however, based 
on the mutation frequency (4.2% and 20% in primary and secondary PC leukaemia, respectively), it 
appears difficult to outline their role in high-risk myeloma.  
 
TP53 
We identified 14 non-synonymous somatic variants in 7.3% (12/163) of cases (Table 6, Figure 12D): 
ten mutations were single nucleotide variations, all of which but one (introducing a premature stop 
codon in PCL-037) were missense mutations. The remaining four mutations were nucleotide 
deletions involving 2, 6, 10 and 82 base pairs respectively, only one of which (6-bp deletion in PCL- 
037) caused an amino acid deletion without alteration of the reading frame. 
Mutation frequencies were 3.1% (4/129), 25% (6/24), and 20% (2/10) in MM, pPCL and sPCL 
patients, respectively (Freeman-Halton test, P = 0.0005), in line with the notion that TP53 mutations 
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are associated with aggressive forms of PC dyscrasias and have a role in tumor progression than 
initiation85, 86. 
Exon 8 was the most frequently affected by mutations (5 variants), followed by exons 5 and 7 (3 
variants each), and exons 4, 6 and 10 (one variant each), whereas no variants were found in exon 
9. With the exception of the nonsense mutation W91* in case PCL-037 (localized in the SH3-
like/Pro-rich structural motif) and the 10-nt deletion spanning intron 9-exon 10 junction in case 
PCL-017, all other variants targeted the DNA binding domain. In regards to the four nucleotide 
deletions identified, only one (T155_R156del in PCL-037) is reported in the IARC p53 website 
(http://www-p53.iarc.fr/index.html)130, and none has been described in other MM series. In 
contrast, all ten single nucleotide variations found in our study are listed in the dataset of somatic 
mutations in sporadic cancers of the IARC database. Each of the variants is carried by a single 
patient in our cohort.  
We evidenced that mutations cluster in the DNA binding domain; I195 and R273 are the most 
frequently mutated residues (I195T detected in three cases and I195M in one; R273H in two 
patients, and R273L and R273C each in one case), followed by P278 (P278S recurring twice, and 
P278L once), R248 (R248Q and R248W in one patient each) and E285 (E285K in two cases). 
Furthermore, virtually all the missense mutations identified in our study are classified as non-
functional130 in the IARC database (see Materials and Methods).  
Noteworthy, we detected the occurrence of two concomitant TP53 mutations in two patients of 
our dataset. In particular, PCL-037 carried the nonsense mutation W91* at a VAF of 47.3% and a 2-
aa deletion (T155_R156del) at a VAF of 49.2%, suggesting the occurrence of both mutations 
virtually in the entire tumor population (due to the experimental design, it is not possible to 
determine whether the mutations are carried on two different chromosomes or on the same allele). 
MM-213 harbored a 82 nt-deletion (at VAF of 8.2%) comprising the last 50 nucleotides of exon 7 
and the first 32 nucleotides of intron 7 and putatively originating an in frame amino acid deletion 
and altered splicing (due to the loss of a splice donor site), and a two-nucleotide deletion (at VAF 
of 2.6%) in exon 8 causing frameshift (A276Lfs*29).  
 
 
 
 
 
Figure 12. Representations of the mutations identified in MM/PCL patients (in the upper part of the figure) including overview of the literature (in the lower part 
of the figures). Amino acid changes caused by mutations found in our series are indicated. (A) BRAF mutations. RBD: Raf-like Ras-binding domain (156 – 226aa); 
C1_1: Phorbol esters/diacylglycerol binding domain (C1 domain) (235 – 282aa); Pkinase_Tyr: Protein tyrosine kinase (457 – 714aa). (B) DIS3 mutations. PIN_4: 
PIN domain (66–195aa); RNB: RNB domain(467 – 797aa). To be continued. 
  
 
 
 
Figure 12_continued. (C) FAM46C mutations. NTP_transf_7: Nucleotidyltransferase (17 – 336aa). *The alteration S302_R312delinsTK is the result of three different 
deletions carried on the same allele in MM-049 patient (see text). (D) TP53 mutations. P53_TAD: P53 transactivation motif (5 – 29aa); P53: P53 DNA-binding 
domain (95 – 289aa) P53_tetramer: P53 tetramerisation motif (319 – 358aa). Mutation types and corresponding color codes are as follows: Missense Mutations 
green, Truncating Mutations black; Inframe Mutations  brown. Mutations depicted in the main dataset83 63 65 64 71, 79, 80 purple. 
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Correlation with major chromosomal aberrations 
Correlations of the analysed mutations with clinical and molecular charachteristics of the patients 
are reported in Table 7. 
There was no significant association for BRAF mutations with any molecular lesion. 
The NRAS mutations showed only a weak negative association with MAF/MAFB translocations 
(P=0.0775), and chromosome 17p deletions were less frequent in KRAS-mutated samples 
(P=0.0019). The latter were also characterized by more frequent hyperdiploidy (P=0.0124), 
although this association disappeared when the analysis was restricted to the MM samples alone 
(data not shown), probably because of the low prevalence of hyperdiploidy in the PCL samples.  
Next, based on VAF, sample purity, and, if available, DNA copy number at BRAF, NRAS or KRAS 
genomic loci, we estimated the expected fraction of MM cells harboring each identified mutation. 
We then compared it with the percentage of CD138+ cells carrying main cytogenetic alterations 
(such as IGH translocations, hyperdiploidy, deletion of chromosome 13 or 1p, or 1q gain) as 
assessed by FISH (data not shown). In such a way, we found that one of the following scenarios 
(observed at quite comparable frequencies in our series) occurred in most of the cases: (i) the same 
fraction of cells (corresponding to the whole tumor clone or to a part thereof) was affected both by 
mutations and other chromosomal lesions, or (ii) mutations occurred in a subclone of MM cells 
harboring other alterations.  
A positive association between DIS3 mutations and IGH translocations was observed (P value = 
0.0046), particularly with the t(11;14) (P value = 0.0198), and a lower occurrence of hyperdiploidy 
among DIS3-mutated cases (P value = 0.025). Conversely, we were unable to find any association 
with 17p deletion, 1q gain or 1p loss. Although not significantly associated with 13q14 deletion, 
DIS3 mutations occurred in several cases carrying this chromosomal alteration. Specifically, 19 of 
the 33 (57.6%) DIS3-mutated patients harbored del(13q14). For eight of them, genome-wide DNA 
profiling data were also available95, 110, indicating that in all but one case (PCL-019) the chromosomal 
deletion included the DIS3 locus. Interestingly, VAFs around 100% were exclusively observed in a 
fraction of patients (10/19) with 13q deletion (and in all likelihood with heterozygous deletion of 
the DIS3 locus). In the other cases, i.e. the remaining del(13q14) samples (9/19) and all the 14 
patients disomic for chromosome 13, the VAFs we found were indicative of mutations occurring in 
hemizygosis in tumor subclones or carried in heterozygosis either by all or by a fraction of 
myelomatous cells. 
We were unable to find any association of FAM46C mutations with major cytogenetic lesions, not 
even hyperdiploidy. In our series, 1p loss was investigated in 15/18 mutated cases by FISH using a 
probe mapping at 1p32.3. Only one case (MM-334) tested positive. Genome-wide DNA profiling 
analysis110, performed in 11/15 patients, showed a complete concordance with cytogenetic data; 
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furthermore, it indicated that loss of FAM46C locus occurred in MM-334 and in an additional case 
(PCL-011) found to be disomic by FISH, but showing a del(1p11.2-1p31.3) by single nucleotide 
polymorphism array110. In line with these data, MM-334 and PCL-011 had VAFs of 100% and 70%, 
respectively.  
As regards the correlations with the occurrence of TP53 mutations, IGH translocations (particularly 
MAF-translocations) were found to be more frequent in TP53-mutated cases compared with the 
whole series (92% versus 50%, P=0.0024). TP53 mutations were negatively associated with 
hyperdiploid status: no hyperdiploid cases among the TP53-mutated ones versus 33% in the entire 
cohort, P=0.009. However, the low TP53 mutation prevalence in MM did not allow limiting 
contingency analyses to this class. As regards 17p deletion, a strong association of gene mutation 
with the deletion of the remaining allele was observed: in fact, deletion of TP53 locus globally 
affected 10.6% of cases [4.7% (6/128) of MM, 29.2% (7/24) of pPCL and 44.4% (4/9) of sPCL patients 
respectively], while its prevalence reached 58% in TP53-mutated subset (P<0.0001). Overall, TP53 
inactivation as a result of gene deletion and/or mutation occurred in 7% of MM, 37.5% of pPCL and 
44.4% of sPCL patients; in particular, the two lesions were simultaneously present respectively in 
0.8%, 16.7% and 22.2% of cases, causing biallelic gene inactivation. 
        
 
 
Table 7. Clinical and molecular characteristics of the total MM/PCL patients analyzed for BRAF-NRAS-KRAS-DIS3-FAM46C-TP53 mutations.*Significance was 
assessed by Freeman-Halton extension of Fisher's exact test for disease type, and by Fisher’s exact test for all other variables. 
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Longitudinal analysis of mutations  
In order to gain further insights into the longitudinal status of mutations, we analyzed 19 patients 
for whom BM specimens were collected at two different timepoints: in particular, fourteen MM 
and two pPCL cases collected both at onset and at relapse; two MM patients at onset and at 
leukemic transformation, and one patient at early and relapsed leukemic phase of MM (Table 8 
and Figure 13). The second specimen in each case was collected after at least one line of treatment 
with various regimens.  
In six cases (MM-239, M-263, MM-271, MM-282, MM-286, and MM-281), BRAF/NRAS/KRAS were 
wild-type at both timepoints. Four of the remaining patients had one mutated gene (BRAF in PCL-
026, NRAS in MM-334, and KRAS in PCL-038 and MM-442) at a quite constant load throughout 
disease course. Others showed the appearance or disappearance of NRAS and KRAS variants with 
low VAFs (the occurrence of KRAS G12A and G12R in MM-340; the occurrence of KRAS Q61L in MM-
200, which also retained KRAS Q61H at a quite constant VAF; the loss of KRAS G12S in MM-004; the 
loss of KRAS G13D in MM-151, which also stably carried KRAS Q61H; the loss of NRAS Q61K in MM-
327, which also harbored the KRAS Q61H mutation in about 40% of the sequencing reads at both 
timepoints) (Figure 13A-B-C). A reduction in the mutational load of a fully clonal variant (KRAS 
Q22K, with an allele frequency of 50% at MM onset and 31% at relapse) was found in one case 
(MM-280) (Figure 13B). Interestingly, the disappearance of a high frequency mutation was 
associated in all cases with the occurrence/clonal expansion of a further mutation in another gene 
of the pathway (the loss of KRAS G12D in MM-429, which acquired the NRAS Q61R mutation; and 
the loss of KRAS G12V in MM-146, which showed a concurrent increase in the allele frequency of 
NRAS Q61H from 8% to 41%) (Figure 13A-B). Notably, the leukemic transformation in MM-295 was 
accompanied by a dramatic increase in the VAF of NRAS G12D (9% to 100%), whereas the mutation 
burden of the co-existing BRAF D594N variant remained stable at about 50% (Figure 13A).  
Fifteen out of the 19 cases displayed a wild type DIS3 status at both timepoints, while one patient 
(MM-281) carrying the R780K variant showed a quite constant VAF during disease course (36.8% 
mutated reads at diagnosis, and 47.56% at leukemic transformation) (Figure 13D). MM-004, wild 
type at onset, acquired a missense mutation affecting a fully conserved amino acid residue 
downstream the RNB domain and suggested to be of functional relevance (A827P); this SNV was 
detected in 97.1% of the sequencing reads at relapse. This patient showed two copies of 
chromosome 13 both at onset and at relapse, and the other cytogenetic lesions remained stable 
during disease progression. A considerable increase in mutation burden was observed in MM-263, 
with R467Q mutation occurring in 31.1% of reads at onset and 81.9% at relapse (this case also 
carried a frameshift mutation at the same position with VAF=5.93% at diagnosis, which disappeared 
at relapse). Finally, MM-340 carried three variants at onset (L48_A56del, A751D and R689Q at VAF 
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of 54.86%, 45.71% and 2.20%, respectively), two of which (L48_A56del and A751D) remained stable 
while the third (R689Q) was no longer detectable at relapse (Figure 13D). The disappearance of 
mutations at high allele frequency at onset was never observed in our cohort.  
For FAM46C mutations, in three cases, all mutated at onset, we observed the presence of primary 
mutation at a quite constant VAF, or its clonal reduction/disappearance (Figure 13E). Unlike the 
findings reported by Kortum et al (2015) and Bolli et al (2014), the acquisition of FAM46C mutations 
over time was never observed in our cohort.  
The analysis of these 19 cases revealed the acquisition of non-functional missense mutations 
(undetectable in the corresponding samples analyzed by NGS at diagnosis) in the DNA binding 
domain in three cases (Figure 13F). Specifically, the longitudinal analysis detected the substitutions 
P278T (VAF = 26.3%) in the myeloma patient MM-280 at relapse, F270L (VAF=97%) at the time of 
leukemic transformation in the myeloma patient MM-281, and K120E (VAF=22.1%) in the pPCL 
patient PCL-038 at relapse, respectively (Figure 13F). Notably, genome-wide DNA copy number 
data were also available for MM-281, indicating two interstitial deletions of 17p arm not involving 
TP53 locus present at sub-clonal level in the sample at onset, and then detecting a larger deletion 
spanning from 17p12 to 17pter in virtually all cells of the later sample.  
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Table 8. Mutation status of analyzed genes 19 sequentially analyzed patients. 
  
 
Figure 13. Changes of BRAF (A), NRAS (B), KRAS (C), DIS3 (D), FAM46C (E) and TP53 (F) mutational burden during disease progression. Allele frequencies of each 
variant are plotted at both time points for patients found mutated at diagnosis and/or relapse. The VAFs of mutations co-occurring in an individual patient are 
identified by the same color.
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Expression of variants on cDNA  
In order to assess whether the identified mutations were actually expressed, we sequenced those 
of our mutated cases for whom biological material was available. In particular, we were able to 
evaluate at transcriptional level 7 BRAF, 20 DIS3 and 17 FAM46C variants, respectively (Figure 14). 
Specifically for BRAF gene, all variants but one were detected in RNA transcript, the only variant 
not identified had a VAF of 4.7% in genomic DNA in PCL-028 (D594E) (Figure 14A). In relation to 
DIS3 gene, 16/20 (80%) evaluated variants were confirmed at transcriptional level (Figure 14B). 
Notably, all the variants detected at VAFs higher than 6% on genomic DNA were also identified at 
RNA level, while none of the five tested low-frequency genomic mutations (VAFs ranging from 
1.95% to 5.96%) was detected on cDNA (Figure 14A-B). Overall, as regards expressed variants, 
mutant allele frequencies detected at gene and transcript level showed a good correlation (Pearson 
correlation coefficient=0.96 for both BRAF and DIS3 gene).  
Notably for DIS3, the aforementioned increase in mutation burden from diagnosis to relapse 
observed in MM-263 for the variant R467Q was accompanied by a doubling of the amount of 
expressed mutant allele (Figure 14B).  
Specifically for FAM46C gene, all evaluated variants were detected and NGS analysis showed higher 
percentages of variant alleles in RNA transcripts compared to genomic DNA in some cases, and 
revealed that also mutations at low VAFs were expressed (Figure 14C). The finding that FAM46C 
mutated alleles had detectable biological expression, and in some cases seemed to be even 
preferentially transcribed, suggests that the mutations identified herein may have functional 
implications.  
Overall, the NGS results indicated that the VAFs detected in genomic DNA and retro-transcribed 
RNA were significantly linearly correlated with a Pearson correlation coefficient of 0.85 (Figure 
14D).  
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Figure 14. Mutations in BRAF (A), DIS3 (B) and FAM46C (C) detected on genomic DNA and cDNA. 
Percentages of variant sequencing reads identified by NGS analyses of genomic DNA and 
retrotranscribed total RNA. (D) Correlation between VAFs detected on genomic DNA and cDNA 
in all genes. 
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Distribution of BRAF, NRAS, KRAS, DIS3, FAM46C and TP53 gene mutations among 
MM/PCL patients 
Considering on the whole the three analyzed genes, BRAF, KRAS and NRAS, the MEK/ERK signalling 
pathway was affected by mutational events in more than half of the cases (96/167, 57.5%), being 
more frequent in sPCL (7/11, 63.6%) and MM (79/132, 59.8%), and relatively less frequent in pPCL 
(10/24, 41.7%). We identified 13 samples with concomitant mutations in two genes: three cases in 
BRAF and NRAS, five in BRAF and KRAS, and five in NRAS and KRAS. In all patients, the co-existing 
mutations had different VAFs, thus supporting the occurrence of tumor subclones. Notably, five of 
the eight BRAF variants in D594 that are predicted to cause BRAF inactivation131 co-existed with a 
NRAS or KRAS mutation.  
Similar to FAM46C, DIS3, another gene commonly mutated in MM, is an RNA-binding protein. The 
molecular mechanism(s) in which FAM46C and DIS3 are involved and the putative targets are yet 
to be determined, although they have been described to couple RNA translation with 
degradation132. In our cohort, three out of 18 FAM46C mutated cases harbored simultaneous DIS3 
mutations (only in one case both alterations had high VAF)133. Overall, we observed mutations in 
these two RNA-binding proteins in 30% of patients, further supporting the hypothesis of the 
involvement of translational control in MM pathogenesis63.  
A fraction of TP53 mutations co-occurred with variants affecting other MM driver genes (Figure 
15). Indeed, two TP53-mutated cases carried also mutations in DIS3, and another one was 
simultaneously mutated in TP53, NRAS and FAM46C genes. However, TP53 mutations were not 
positively associated with those of any other gene; on the contrary, the absence of TP53 mutations 
in KRAS-mutated cases was deemed statistically significant (P=0.019).  
Concerning variant allele frequencies, in TP53-mutated patients positive for del(17p) VAFs were 
almost always indicative of the exclusive presence of the mutated allele. On the contrary, in 
mutated cases at onset and disomic for chromosome 17, VAFs ranged from 2.65% to 100%, 
suggesting the occurrence of minor mutated subclones in MM-213 and MM-343. Furthermore, we 
observedthe presence of clonal heterozygous mutations in PCL-037; the predominance of mutated 
allele in PCL-004; and apparent copy number-neutral loss of heterozigosity in MM-262. As stated 
above, in the three patients longitudinally analyzed and showing in the late sample the emergence 
of TP53 mutations not visible in the earlier sample, VAFs were of 22.1%, 26.3% and 97%, 
respectively. 
   
 
 
 
Figure 15. Heat map distribution of TP53, DIS3, FAM46C, BRAF, KRAS and NRAS gene mutations among MM/PCL patients. The rows correspond to the indicated 
genes, and columns represent individual MM or PCL samples, which are color-coded on the basis of gene status (white: wild-type; light red: Sanger-undetectable 
mutations; dark red: Sanger-detectable mutations).
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Transcriptomic profile of patients with BRAF/NRAS/KRAS/DIS3-mutations 
In order to identify the transcriptional profiles related to BRAF, NRAS and KRAS mutations in 
primary tumors, we used microarray technology to investigate a large number (n = 142) of the 
samples analyzed by NGS. Assuming that alterations in a limited number of myeloma cells do not 
appreciably affect gene expression, we arbitrarily chose a lower VAF cut-off value of 20%, thus 
resulting in the comparison of 60 wild-type versus 68 mutated patients. Eighty-six genes resulted 
differentially expressed (Table 9A): 27 up- and 59 down-regulated in the mutated cases. 
Particularly, 18 genes emerged at the highest stringency level. Interestingly, functional enrichment 
analysis revealed the involvement of a statistically significant fraction of modulated transcripts in 
MAPK signalling (PRKD2, SPRED2, MAPKAPK2, CD300A, ARL6IP5, DUSP6, PPM1L, GRB2, LAMTOR3, 
SPRED1, LYN, EDN1, RASGRP1 and ACVR1B) at both biological process (GO:0000165, q-value=3.29E-
03) and pathway level (198779 WikiPathway, q-value=1.33E-02) (Table 10). 
Principal component analysis based on the expression of the 18 most statistically significant genes 
allowed a good separation between mutated and wild-type patients, without any apparent gene-
specific discrimination (Figure 16).  
 
 
Figure 16. Multidimensional scaling plot using the most significant genes (n = 18) differentially 
expressed between BRAF/NRAS/KRAS-mutated and wild-type patients. Each point represents a 
single sample and is coloured on its type (patient/normal control) and mutation status as 
measured by sequence analysis. In the case of co-existing mutations of which only one had an 
allele frequency of >20%, the color corresponds to the gene with the highest mutational load.  
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Table 9. Modulated genes between (A) BRAF/NRAS/KRAS mutated and wild type patients and (B) 
DIS3-wild type and mutated patients. *Differentially expressed gene at the highest stringency 
level. ‡Negative scores indicate downregulated genes in mutated cases. 
  
Table 10. Enriched biological processes in the MAPK mutation-associated 86 gene signature (q value<0.005). 
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Notably, a few tumors not affected by mutations in any of the three genes (but possibly mutated 
in other genes of the pathway) showed the same activated MAPK pathway transcriptional profile 
as the mutated cases, as it has been found in other cancers134. Conversely, some mutated samples 
had a wild-type-like expression profile, including 10 cases carrying mutations with a low VAF; MM-
295 (BRAF D594N); and PCL-026, harboring both D594N and E586K BRAF mutations. Interestingly, 
NGS analysis of PCL-026 indicated that both variants were carried on the same allele, thus 
suggesting that the putative abrogation of BRAF negative regulation generated by the E586K 
substitution may not lead to increased BRAF signaling because of the concomitant occurrence of 
the D594N mutation. 
To identify transcriptional gene profiles related to DIS3 mutations, we performed a two-classes 
supervised analysis, choosing to set at 20% the lower VAF cut-off, thus leading the comparison of 
89 wild type versus 13 mutated patients. This analysis revealed that 119 genes (q-value < 0.1) (Table 
9B) were differentially expressed between the two groups; among them, 28 genes were identified 
at stringent level (q-value=0) and they are depicted in the heatmap (Figure 17).  
 
 
Figure 17. Heatmap of the 28 differentially expressed genes identified at q-value=0 by SAM two-
class analysis of 102 MM patients stratified based on the presence of DIS3 mutations. In the 
heatmap, the color-scale bar represents the relative gene expression changes normalized by the 
standard deviation, and the color changes in each row represent gene expression level relative 
to the mean across the samples.  
 
Notably, all transcripts were up-regulated in mutated cases. Interestingly, 74 were protein-coding 
genes, while one gene was of unknown type and 44 were non-coding RNAs/pseudogenes. 
In particular, this latter class of modulated transcripts included nine antisense RNAs (ARHGAP5-
AS1, C21orf119, DLGAP1-AS1, HEXA-AS1, ILF3-AS1, LOC645212, MATN1-AS1, TAPT1-AS1, ZNRD1-
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AS1), seven pseudogenes (CATSPER2P1, FLJ37201, GNRHR2, GVINP1, HTATSF1P2, NUDT9P1, 
PRORSD1P), six long intergenic non-protein-coding RNAs (FLJ30403, TP53TG1, LINC00167, 
LINC00173, LINC00528, LOC100129726), five small nuclear RNAs (RNU11, RNU12, RNU4ATAC, 
RNU5D-1, RNU5F-1), two microRNAs (MIR23A and MIR320A), one microRNAhost gene 
(MIRLET7BHG), and a group mainly consisting of uncharacterized loci and open reading frames. We 
then explored whether these transcripts belonged to specific functional subgroups. Remarkably, a 
significant fraction of them was involved, like DIS3 itself, in single-stranded RNA binding function 
(namely, PAT2L, DHX58, DDX60 and KHDRBS2; P value = 1.01E-04) (Table 11). Beyond this specific 
molecular function, several other up-regulated genes in DIS3-mutated patients are implicated in 
RNA physiology: in particular, PAN2, POP1, RBM45 and the aforementioned PATL2 and KHDRBS2 
genes are involved in RNA metabolism; APOBEC3F and APOBEC4 encode RNA editing enzymes; 
whereas RNU11, RNU12 and RNU4ATAC are spliceosome subunits. Notably, DHX58, DDX60 and 
APOBEC3F genes, along with IFIT1, IFIT3, IFI6, and OASL, are part of interferon-mediated anti-viral 
response. 
 
Table 11. Selected significantly enriched gene ontology terms in the DIS3 mutation-associated 
gene signature (q-value < 0.05, Benjamini Hochberg correction). 
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Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias 
A CAPP-seq ultra-deep targeted NGS approach was developed to genotype a large gene panel 
specifically designed to maximize the mutation recovery in PC tumors, and compared the 
mutational profiling of cfDNA and tumor gDNA of purified PCs from BM aspirates in a consecutive 
series of 28 patients representative of different clinical stages of PC tumors, with clinical and 
molecular characteristics consistent with an unselected cohort of PC dyscrasia patients (Table 12). 
In particular, we collected the three type of biological material from two had MGUS, five sMM, and 
21 symptomatic MM patients. The sampling was done at diagnosis in 25 patients, and during the 
course of the disease in three MM cases (Table 12). The targeted resequencing gene panel included 
coding exons and splice sites of 14 genes: BRAF, CCND1, CYLD, DIS3, EGR1, FAM46C, IRF4, KRAS, 
NRAS, PRDM1, SP140, TP53, TRAF3, ZNF462 (target region: 31 kb). 
  
Table 12. Clinical details of the 28 patients analyzed by Illumina Miseq. ΔThe ISS was adopted; ‡ND: newly diagnosed, RR: relapsed/refractory; 
†Paraprotein; FLC, free light-chain; *del(13), del(17), 1p loss and 1q gain were determined by FISH. °HD= presence of the hyperdiploid status on the 
basis of FISH evaluation criteria; na: not applicable. 
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cfDNA was detectable in plasma samples with an average of 11 000 haploid genome-equivalents per 
mL of plasma. The amount of cfDNA correlated with clinic-pathological parameters reflecting tumor 
load/extension, including BM PC infiltration (Pearson correlation coefficient=0.6, P=0.0007; Figure 
18A), and clinical stage. Indeed, patients presenting with ISS stage 3 had significantly higher amounts 
of cfDNA compared with MGUS/sMM samples and MM cases at ISS stages 1-2 (P=0.01; Figure 18B, 
Mann-Whitney test). The application of our targeted ultra-deep NGS approach for plasma cfDNA 
genotyping resulted in ≥90% of the target region covered ˃1 000X in all plasma samples, and ≥90% of 
the target region covered ˃2 000X in 23/28 (Figure 19 and Table 13).  
 
 
Figure 18. (A) Correlation between cfDNA amount and bone marrow plasma cell infiltration. (B) 
cfDNA amount according to diagnosis/risk stratification: the levels of cfDNA are significantly higher 
in MM patients at ISS stage 3 compared with MGUS/sMM samples and MM cases at ISS stages 1-2 
(P=0.01; Mann-Whitney test).
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Figure 19. Coverage across the target region. Depth of coverage (y axis) across the target region 
(x axis) by CAPP-seq of (A) gDNA from the germline (granulocytes) samples, (B) tumor gDNA from 
bone marrow plasma cells, and (C) plasma cfDNA. Each dot represents the sequencing depth on 
that specific position of the target region of one single individual sample. The solid blue line 
shows the median depth of coverage, while the dash blue lines show the interquartile range. 
The dashed red line shows the 2000X coverage. 
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Table 13. Percentage of target region covered ≥1000X and ≥2000X in distinct patient samples. 
Abbreviations: GL, normal germline DNA from granulocytes; PCS, tumor genomic DNA from 
plasma cells; PL, cfDNA from plasma. 
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Overall, within the interrogated genes, 18/28 (64%) patients had at least one non-synonymous 
somatic mutation that was detectable in cfDNA (Figure 20A and Table 14A); 28 total variants were 
identified, with a range of 1-4 mutations per patient. Quite consistent with the typical spectrum of 
mutated genes in MM, plasma cfDNA genotyping revealed somatic variants of NRAS in 25%; KRAS 
in 14%; TP53, TRAF3 and FAM46C in 11%, respectively, CYLD and DIS3 in 7%, respectively, and BRAF 
and IRF4 in 4% of cases, respectively. Variants in NRAS, KRAS and BRAF genes occurred in a mutually 
exclusive manner. TP53 mutations were positively associated with the deletion of the remaining 
allele as revealed by FISH on purified PCs (P=0.02, Fisher-exact test).  
To validate the tumor origin of mutations discovered in cfDNA and to derive the accuracy of our 
approach in resolving tumor genetics, the genotype of cfDNA was matched with that of gDNA from 
purified BM PCs in all the 28 patients. Sequencing of tumor gDNA identified 39 somatic mutations 
in 20/28 (71.4%) patients (Figure 20B). cfDNA genotyping correctly identified 72% of mutations 
(n=28/39) that were discovered in tumor PCs (Figure 22A), and overall the variant allele frequencies 
in plasma samples correlated with those in tumor biopsies (Pearson correlation coefficient=0.58, 
P=9.6e-05; Figure 22B). Notably, the remaining BM PCs’ confirmed mutations not discovered in 
cfDNA (n=11) had a low representation in the tumor (median allelic frequency: 2.5%; range: 1.1-
4.96%) (Table 14B and Figure 20C). Consistently, based on ROC analysis, cfDNA genotyping has the 
highest sensitivity in detecting tumor PCs’ confirmed mutations when they are represented in at 
least 5% of the tumor alleles (Figure 22C). Above this threshold, the sensitivity of cfDNA genotyping 
reached 100%. Noteworthy, cfDNA genotyping was still able to detect almost half (10/21) of 
mutations of low-abundance in tumor PC (i.e. allelic frequency <20%), indicating a good capacity of 
cfDNA to mirror also the subclonal composition of the tumor. In none of the cases cfDNA 
genotyping identified additional somatic mutations not detected in the purified BM PCs. 
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Figure 20. Overview of the mutations identified in the PC dyscrasia series. (A) Mutations detected 
in plasma cfDNA; (B) mutations detected in tumor gDNA. Each column represents one tumor 
sample and each row represents one gene. The fraction of tumors with mutations in each gene 
is plotted (right). The number and the type of mutations in a given tumor are plotted above the 
heat map. (C) Bar graph of the allele frequencies in tumor gDNA of the variants that were 
discovered in plasma cfDNA (red bars) or missed in plasma cfDNA (gray bars). The dashed line 
tracks the 5% allelic frequency threshold. 
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Table 14. Somatic non-synonymous mutations discovered by cfDNA genotyping and their 
validation in tumor gDNA (A) and those discovered in tumor gDNA genotyping and missed in 
plasma cfDNA (B). Abbreviations: CHR, chromosome; REF, reference allele; VAR, variant 
allele.*Absolute chromosome coordinates of each variant based on the hg19 version of the 
human genome assembly. 
 
 
  
 
 
Figure 22. Concordance between plasma cfDNA and tumor gDNA genotyping. (A) The fraction of tumor biopsy–confirmed mutations that were 
detected in plasma is shown. Patients are ordered by decreasing detection rates. The red portion of the bars indicates the prevalence of tumor 
biopsy–confirmed mutations that were detected in plasma cfDNA. The gray portion of the bars indicates the prevalence of tumor biopsy-confirmed 
mutations that were not detected in plasma cfDNA. (B) The mutation abundance in plasma cfDNA vs the mutation abundance in tumor gDNA is 
comparatively represented in the scatter plot for each identified variant. (C) ROC analysis illustrating the performance of gDNA genotyping in 
discriminating the ability of cfDNA genotyping to detect biopsy-confirmed mutations according to the variant allele frequency of mutations in tumor 
gDNA.
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MM is an incurable hematological malignancy, accounting for 10% of all hematological tumors. It is 
characterized by a wide clinical spectrum, and by a highly heterogeneous genetic background 
featuring a deep instability, at both karyotypic and mutational level. As regards in particular the 
mutational landscape, the emerging scenario from recent NGS studies in MM patients indicated 
the lack of a universal driver mutation but several recurrently mutated genes belonging to key 
pathways involved in the disease, such as the MAP kinase pathway. What is most impacting are the 
clinical implications of NGS-derived data. In fact, a number of mutations have been identified that 
are targetable with commercially available agents, associated with poor or favorable prognosis, or 
responsible for drug resistance. Therefore, somatic mutations may represent novel markers to 
improve risk prediction and guide towards the choice of the most appropriate therapeutic strategy, 
taking full advantage of the available treatment options, in the perspective of applying precision 
medicine as ultimate goal. 
MM genotyping has so far relied on the analysis of purified PCs from the BM aspirate from a single 
anatomical site, which may fail in capturing the entire mutational repertoire of PCs as they can 
localize into multiple and genetically heterogeneous foci. Furthermore, it is associated with 
technical hurdles and patient discomfort, which are limiting its transfer in the routine diagnostic 
workup of patients. For these reasons, alternative and complementary approaches that could 
overcome both the abovementioned limitations are required. In this context, the analysis of cfDNA, 
that is shed into the PB by tumor cells and contains a representation of the entire tumor genome, 
is one promising possibility, implying obvious advantages in terms of accessibility and ability of 
capturing the whole tumor heterogeneity. 
The plan of this project was to test the hypothesis that cfDNA may represents an accessible source 
of tumor DNA for the sensitive identification of genetic biomarkers in PC dyscrasia by pursuing the 
following specific aims: 
 evaluation of the incidence of mutations in some driver genes (KRAS, NRAS, TP53, BRAF, 
FAM46C and DIS3), as suggested by several recent massive DNA sequencing studies 63 65 64, 
71, in a large and representative cohort of patients at different stages of PC dyscrasia; 
 comparison of the mutational profiling of cfDNA and BM testing in a small series of patients 
representative of different clinical stages of PC tumors to assess the proof of principle that 
the MM mutations are detectable in plasma, so that this approachcan be used as a 
powerful non-invasive biomarker. 
 
Regarding the first point, in the study population of 167 cases with different PC tumors, BRAF 
mutations were identified in 12%. The mutation frequency in our series of patients with MM at 
onset (10.6%) was more consistent with that found in WGS/WES studies64, 65, 71 (on average in 8.7% 
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of cases) (Figure 23) compared with other studies73, 135. Our NGS analysis identified mutations with 
a low VAF and a number of variants other than the classic V600E (found in seven cases), which is 
carried by less than half of the BRAF-mutated patients, unlike what observed in other tumor types, 
i.e. melanoma, colorectal cancer, and papillary thyroid carcinoma. This substitution is the most 
frequent mutation, reported to destabilize the hydrophobic interaction between the glycine-rich 
loop and the activation segment, thus locking the protein in its active conformation and increasing 
BRAF kinase activity119, 136 (Figure 12A). Published functional data indicate that most BRAF 
mutational events are responsible for the activation of MEK-ERK pathway, which is also caused by 
alterations in NRAS or KRAS (whose involvement in disease pathogenesis has already been 
extensively proven)113, 128, 135 in an even more substantial percentage of patients. 
We detected genetic alterations in ERK signalling in 57% of our patients, thus confirming the crucial 
role this pathway plays in MM development. In line with the findings of the most recent sequencing 
studies64, 65, 71, our analysis revealed concomitant substitutions in more than one of the investigated 
genes in 13 patients, although their simultaneous occurrence at high VAF was rare. Interestingly, 
the concomitant occurrence of five of the eight D594BRAF variants with mutations in KRAS or NRAS 
may be explained by the experimentally described synergy of kinase-dead BRAF mutations involving 
D594 and oncogenic RAS. Their cooperation in inducing tumor progression, indeed, has been 
demonstrated in a murine model of melanoma137, thus confirming the hypothesis that the high 
frequency of this inactivating mutation (also observed in our MM patient cohort) is incompatible 
with a random event. Furthermore, serial analyses of BRAF, N- and K-RAS mutations during disease 
progression revealed a slightly more complex scenario than that found by Bolli et al.64, who 
described either clonal variants at both timepoints or the presence of acquired/increased variants 
in the later sample, in line with the expected positive selection of mutated subclones. Besides these 
patterns, we also observed the disappearance of variants with relatively high VAF values, but always 
occurring concurrently with the emergence/clonal expansion of an additional mutation in another 
gene of the pathway. 
In line with recent WES studies, these data indicate that, although involving driver genes, MAPK 
mutations can be clonal (compatible with early events) in some patients or subclonal (compatible 
with late events) in others64, 65, and may occur at variable times during tumor evolution compared 
to the other molecular lesions. The activation of the MEK-ERK pathway as a result of BRAF and RAS 
mutations identified by NGS was confirmed by the GEP data of the same patients, indicating that 
the MAPK cascade is one of the most enriched biological processes involving genes that are 
differentially expressed between mutated and wild-type patients. Together with the detection of 
the majority of BRAF genomic variants at cDNA level, this highlights the particular importance of 
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alterations in this pathway in terms of both occurrence and phenotypical impact in the context of 
the heterogeneous mutational pattern of MM.  
DIS3 belongs to the human exosome complex and is endowed with both exo- and endonucleolytic 
activities. DIS3 regulates the processing and abundance of all RNA species138. DIS3 mutations were 
globally identified in 20.1% of patients: specifically, mutation prevalence was 18.5% in newly 
diagnosed MM patients, 25% in pPCL at onset, and 30% in sPCL. Interestingly, DIS3 mutation 
frequency seemed to be slightly higher in extramedullary phases (although this difference did not 
reach statistical significance, likely due to the relatively small size of pPCL and sPCL series). The 
prevalence of DIS3 mutations identified here in representative MM cases at onset (18.5%) was 
higher than the prevalence reported for unselected patients’ cohorts in other studies63, 65, 71, 80  
(Figure 23). Most likely, this could be due to the higher depth of coverage of our sequencing 
analysis, especially compared to that usually obtained in WGS and WES experiments. Compared to 
the lower frequency (11%) reported by Weißbach et al.80, who used our same targeted 
resequencing approach, this difference could be due to the exclusion in that study of the variants 
with VAF lower than 8%. We obtained similar results as of Walker et al.79 (18%), who exclusively 
analyzed IGH-translocated patients. Indeed, also in the present series, DIS3 mutations were 
confirmed preferentially associated with IGH translocations and nonhyperdiploid status. 
Of the two functional domains investigated in this study, the RNB domain was slightly more densely 
affected by mutations. The mutations of the RNB domain initially identified in MM by Chapman et 
al.63 interfere with DIS3 ribonucleolytic activity76. This functional effect could be envisaged also for 
many of the mutations identified by us, based on the bioinformatics predictions and the pattern of 
differential expression between DIS3-mutated and wild type MM cases emerged from the gene 
expression profiling of our cohort. DIS3-mutated MM samples, in fact, displayed the up-regulation 
of several transcripts, including genes involved in RNA interactions and many non-coding 
transcripts. The finding that all the involved transcripts were over-expressed in DIS3-mutated 
patients reflects what reported by several studies analyzing the transcriptional output resulting 
from the mutation or depletion of exosome subunits in other species, and is consistent with the 
RNA degradative activities ascribed to the exosome139-141. In this regard, it is also worth noting that 
substitutions at residues R780, D487 and D488 (demonstrated or supposed to be particularly 
detrimental for protein function) were never observed at genomic VAFs above 50%, neither in the 
present nor in previously published datasets65, 71, 79, 80, suggesting that the exclusive presence of 
such DIS3 mutant forms in the absence of a DIS3 wild type protein might have deleterious cellular 
effects. In general, the lack of a DIS3 wild type allele in mutated cases was uniquely observed in 
some 13q14-deleted MM patients carrying other types of variants. The most affected residue R780, 
replaced by a lysine or by a threonine in three and two cases, respectively, was in line with what 
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reported in previous MM sequencing studies, where this amino acid position was already indicated 
as the major DIS3 mutational hotspot63, 65, 79, 80 and it was also confirmed by the last Walker’s 
work71(Figure 12B). The arginine at position 780 was found involved in RNA binding function129. 
Both R780K and R780T substitutions are recurrent in MM patients of our and previously published 
datasets65, 79, 80, and the former was demonstrated to cause significant aberrations of DIS3 
exonucleolytic activity and growth inhibition in yeast and human cellular models76. Of note, D488 
represents the second most affected residue in DIS3-mutated MM patients when combining the 
results of the previous studies63-65, 71, 79, 80. Interestingly, the adjacent conserved aspartic acid at 
position 487 (D487H mutation found each in one patient) is equally essential for magnesium 
binding, and when substituted with asparagine (D487N) it was reported to completely abolish DIS3 
exonuclease activity in yeast and human cellular models, causing molecular phenotypes 
comparable to the DIS3-R780K mutant76. Other recurrently mutated positions in our series were 
T93, H764, F775, R789 and R820, each targeted in two samples by the same substitution, except 
for H764 (reported to be involved in RNA binding129) showing different amino acid changes. 
Notably, the majority of these recurrently altered residues represent novel DIS3 mutations in MM. 
In fact only the variant F775L has already been reported in another series65. Some of them have 
been already reported as altered in MM (R108, R467, S550)65 or in other cancer types (R820, 
COSM3469577). Among the mutated residues never described before, A751 is involved in RNA 
binding 129. Furthermore, looking at DIS3 mutations in longitudinally analyzed patients (i.e sampled 
at diagnosis and relapse), we observed a similar scenario to that described by Bolli et al.64 for other 
known driver myeloma genes, i.e. the occurrence of clonal variants at both timepoints or the 
acquisition/clonal expansion of variants at the later timepoint, consistently with an expected 
positive selection for the subclones harboring them. Of note, the disappearance at relapse of 
variants found at diagnosis at low allele frequency was only observed in patients carrying additional 
stable/clonally expanding mutations. The limited sample size and the different treatment regimens 
to which the patients were subjected do not allow making assumptions on the possible impact of 
specific therapies on the chances of survival of DIS3-mutated subclones. 
The involvement in MM of DIS3 and FAM46C, which are two of the most recurrently mutated genes 
in the disease (average mutation frequency of 7% and 9.1%, respectively) (Figure 23), was totally 
unexpected prior to the application of massively parallel sequencing.  
Although the significance of its alteration in the disease still needs to be further elucidated, DIS3 is 
considered a potential tumor suppressor in MM based on several findings: the loss of enzymatic 
activity caused by the MM-associated DIS3 mutations that have been functionally characterized76; 
the loss of heterozigosity often involving DIS3 due to simultaneous gene mutations and 
chromosome 13 deletion; and the reported enhanced translation of crucial oncogenes following 
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DIS3 inactivation81. Similar to DIS3, FAM46C is an RNA-binding protein whose exact functions 
remain to be characterized, but potentially regulating gene expression142. FAM46C too has a 
putative tumor suppressor role in MM, as suggested by the deletion of its genomic locus at 1p12, 
occurring in approximately 20% of MM patients83, and the predominantly inactivating nature of 
MM-associated gene mutations. Overall, the significantly recurrent alteration of DIS3 and FAM46C 
suggests a role of translational control processes in the pathogenesis of MM63. The prevalence of 
FAM46C mutations (11.7%) identified in our newly diagnosed MM cohort was similar to that 
described in previous studies63-65, but higher than the one more recently reported by Walker et 
al.71. Interestingly, except for a few codons (D90, L93, L134,K141, E166, G241 and Y291) already 
reported as mutated in independent series65, 71, 83, the majority of altered residues identified in the 
present study represented novel FAM46C mutations in MM. Combining our data with those 
available in the literature for MM63-65, 71, 79, 83, it would appear that the FAM46C coding sequence is 
almost entirely altered by mutations, with the exception of small portions, especially in the N-
terminal region. Overall, the finding that FAM46C mutated alleles had detectable biological 
expression, and in some cases seemed to be even preferentially transcribed, suggests that the 
mutations identified herein may have functional implications. In conclusion, our data strengthen 
the growing evidence that FAM46C is involved in the pathogenesis of MM as a potential tumor 
suppressor, although its role remains to be clarified. 
In the present study, the use of deep NGS in a large representative cohort of MM at diagnosis and 
more aggressive disease stages substantially confirmed the accepted notion85-88 that TP53 
mutations in MM at presentation are rarely detected (3.1% in MM), while their frequency increases 
with disease progression (25% in pPCL and 20% in sPCL). This would be consistent with the 
hypothesis that defective TP53 may cause extramedullary disease96. The enhanced sensitivity of 
our analysis, in fact, was not accompanied by a substantial increase in the mutation rate observed 
in MM cases, consistent with the fact that we did not find many mutations at particularly low allele 
frequency, which could be undetectable by the traditionally used Sanger method. Although we 
cannot exclude that an even greater depth of coverage would eventually bring out further smaller 
mutated subclones, this finding is in line with what reported by other recent NGS studies64, 65, 143. In 
extra-medullary MM, TP53 inactivation was significantly more frequent, as a result of both gene 
mutations and deletions, confirming that these lesions represent late-progression events. Surely, 
alterations of TP53 identify a high-risk population of patients, even in the context of molecularly 
comprehensive risk scoring models71. Although the close association between mutations and 
deletions makes it difficult to understand the prognostic contribution of individual lesions64, 92, 144, 
the recently demonstrated haploinsufficiency of the gene98 may be responsible of TP53 pathway 
deficiency whenever the cells do not have two intact copies of the gene (as a result of both deletion 
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and mutations). Furthermore, taking into consideration the dominant negative effect or gain of 
function of many of TP53 mutations, TP53 functionality appears to be even more compromised. In 
general, the occurrence of mutations even in cases not carrying the deletion supports the 
importance of their assessment in MM patients, given that many anti-MM drugs induce apoptosis 
through multiple pathways that are at least in part dependent upon functional TP53 activation. 
Consistently, we noticed the emergence of a mutation in three of 19 MM/PCL patients analyzed at 
relapse; despite the NGS analysis of the earlier samples, we could not detect at onset minor mutant 
subclones potentially responsible for relapse. Concerning deletion of chromosome arm 17p, its 
frequency in intra-medullary MM patients of our series appears to be lower than that generally 
reported, a finding that could be related to different sample size and patient selection criteria. A 
strong, albeit not absolute, association of gene mutation with the deletion of the remaining allele 
was observed also in our series, in line with previously reported data144. Concerning the type of 
variants, unlike Chng et al.144 and more similarly to what reported by Lodé and colleagues92 and 
other more recent papers64, 65, 71, most of the mutations identified here were single nucleotide 
missense mutations. Differently from many tumor suppressor genes, in human cancers TP53 is 
actually most commonly altered by missense mutations that not only lead to a loss/diminution of 
the wild type TP53 activity, but, since TP53 normally acts as a tetramer, may also function as 
dominant negative inhibitors over any remaining wild type TP53 activity, or even give rise to a more 
aggressive tumor profile through gain of function activity. Gain of function roles in different cellular 
processes have indeed been demonstrated for several TP53 mutants also detected in MM/PCL of 
the present and other published datasets64, 65, 71, 79 (P151S, R248Q, R248W, R273H, R273C, V274F, 
P278S, and R280K)145. MM-associated TP53 mutations are concentrated in the DNA binding 
domain, and the frequency at which amino acid residues are targeted only in part reflects the one 
globally observed in human cancers. Indeed, contrary to what is globally observed in MM, somatic 
mutations affected codon 195 are not among the most recurrent in human tumors.  Notably, the 
substitution I195T, like other tumorigenic mutations in the β-sandwich affecting hydrophobic 
residues in the protein core, was reported to be severely destabilizing146, determining a half-life of 
the unfolding of the mutant protein of less than one minute at 37°C147. Conversely, R273 is one of 
the six residues identified as hotspots for tumorigenic mutations in human cancers; it is generally 
targeted by two predominant substitutions, i.e. R273H and R273C, both of which identified in MM 
cases and preventing DNA binding by the isolated core domain146. With regard to the amino acid 
residue 278, it is one of the essential amino acids for major groove contacts in the pentamer 
sequence of the consensus DNA binding site148. (Figure 12D) The substitution E285K is the most 
common TP53 temperature-sensitive mutation(its wild type TP53 activity is reconstituted at about 
32°C) and is also carried by the RPMI-8226 MM cell line91, 149, 150. Amino acid substitutions R→W and 
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R→Q at the hot spot codon 248 both inactivate the transactivating functions of wild type TP53, 
although it has been demonstrated that they differently contribute to in vitro malignant behavior 
of tumor cells through gain-of-function properties151. 
TP53 is mutated at a significant recurrence rate in all three studies64, 65, 71(on average 8.3%), 
although the mutational frequencies observed in each series are significantly different, and higher 
in series where advanced disease was over-represented64, 65(Figure 23). In fact, as highlighted by an 
NGS-based analysis in a representative cohort including patients with newly diagnosed MM and 
more advanced stages of PC dyscrasia, TP53 mutations are generally rare in MM at onset, and 
conversely constitute a marker of progression, analogously to 17p-deletion. 
 
 
Figure 23: Most significantly mutated genes in MM. Mutation frequencies observed in our MM 
patients is reported in Bordeaux in comparison with frequencies observed in each of the three 
main WGS/WES studies in MM64, 65, 71. 
 
To gain further information about the pattern of evolution underlying relapse in MM, a recent 
longitudinal study investigated by WES, gene expression profiling and high-resolution copy number 
arrays 33 patients enrolled in Total Therapy protocols with the aim to define specific drivers of 
relapse in the precise context of a standard treatment152. Notably, the acquisition/expansion of 
mutations in known MM driver genes (NRAS, KRAS, BRAF) and the biallelic inactivation of tumor 
suppressor genes, especially TP53, proved to be critical events driving relapse through the escape 
form treatment-induced apoptosis and increased proliferation, leading to drug resistance and 
tumor progression. In particular, biallelic events resulting in complete inactivation of TP53 defined 
the group with the worst outcome after relapse. 
Considering on the whole the three analyzed genes, BRAF, KRAS and NRAS, the MEK/ERK signalling 
pathway was affected by mutational events in more than half of the cases (96/167, 57.5%), being 
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more frequent in sPCL (63.6%) and MM (59.8%), and relatively less frequent in pPCL (41.7%). This 
latter finding is consistent with what newly emerged from a recent WES study in a smaller fraction 
of the pPCL patients of the present series89. This studyinvestigating the mutational profiles of a 
fraction of the pPCL patients of the present series (12 pPCL patients enrolled in a multicenter 
prospective GIMEMA Phase II trial www.clinicaltrials.gov as #RV-PCL-PI-350, 
www.clinicaltrialsregister.eu as #EudraCT N° 2008-003246-28) found few genes recurrently 
mutated in two or more samples, confirming a substantial heterogeneity of mutational patterns, as 
observed in intramedullary disease. Mutations in KRAS and NRAS were three-fold less frequent, 
while those in DIS3 and TP53 were till to two-fold more recurrent in pPCL than in MM, and this was 
perhaps at least partly related to different representativeness of cytogenetic abnormalities in pPCL 
and MM series. This work identified DIS3 as one of the 14 statistically significant recurrently 
affected genes with potential driver role in the disease89 and indicated that TP53 impairment 
seemed to lie within a more generalized alteration of cell cycle checkpoints, which involved other 
genes among which the most frequently mutated were ATM, ATR, CDKN1A and BRCA189. 
As far as our study is concerned, we observed that genomic and transcriptional VAFs of BRAF were 
highly concordant in mutated patients. A recent RNA-seq analysis of a subset of patients who had 
previously undergone WES, indeed, has shown that most of the identified mutations occur in genes 
whose expression is very low or undetectable153; in addition, the mutation frequencies at genomic 
and transcriptional levels were found not comparable for many genes153. This new finding further 
strengthens the rationale for BRAF-targeted therapeutic strategies.  
Activating alterations of the BRAF serine/threonine kinase gene have also been recently described 
in WGS/WES studies of MM further extending the evidence of a widespread dysregulation of MAPK 
signalling in the disease63-65, 79. Over the last few years, BRAF has received considerable attention as 
a result of the success of targeted malignant melanoma therapy154, and encouraging preliminary 
results have emerged from exploratory studies of the use of BRAF inhibitors in patients with BRAF-
mutated MM73, 75. Moreover, it is to be hoped that more precise indications concerning its efficacy 
will emerge from the ongoing phase II Basket study (NCT01524978) of vemurafenib in patients with 
BRAF V600E mutation-positive cancers, which also include MM patients155. However, the clinical 
relevance of BRAF and NRAS/KRAS mutations is still unclear. Bolli et al.64 found no signiﬁcant 
survival difference between cases with and without KRAS, NRAS or BRAF mutations, whereas 
Andrulis et al.73 found that overall survival was significantly shorter in their MM patients carrying 
BRAF V600E. Nevertheless, the paradoxically tumor-enhancing effects of BRAF inhibitors in the case 
of sub-clonal BRAF or co-existent BRAF and RAS mutations indicates the need for the accurate 
molecular characterization of patients in order to obtain the most from targeted therapeutic 
strategies. 
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The gene expression patterns observed in our study suggested that identified mutations here are 
actually expressed, as directly assessed by cDNA sequencing of DIS3-mutated patients showing 
comparable mutation burdens at gene and transcript levels. Overall, these data demonstrate the 
ultimate signiﬁcance of the DIS3 gene mutations, differently from what has been suggested for the 
majority of the genetic changes detected by genome-wide approaches in MM, which are found in 
genes that have low or no detectable biological expression153.  
The clinical implications of DIS3 mutations in MM remain to be elucidated. Recently, Weißbach et 
al.80 reported that the occurrence of DIS3 mutations in minor subclones was signiﬁcantly associated 
with a weaker chemotherapy response as compared to the DIS3 mutations in major subclones, 
while globally there was only a slight trend towards shorter median overall survival for DIS3-
mutated MM patients as compared to DIS3 wild type ones. In our series, we had the possibility to 
evaluate the prognostic impact of DIS3 mutations in the group of pPCLs included in a prospective 
multicenter clinical trial114 for whom a 2.8-month follow-up was available, observing no significant 
association with survival or response rate (data not shown). Furthermore, although less prevalent 
in MM, mutations in ATM or ATR genes were lately reported to be associated with a negative impact 
on survival of MM patients enrolled onto the NCRI Myeloma XI Trial, in which the inability to deliver 
an effective apoptotic response to DNA damage represented the most significantly prognostic 
mutational marker71. 
 
As regards the validation of the liquid bopsy as a diagnostic tool, the application of targeted ultra-
deep NGS approach in the prospectively collected cohort of 28 unselected PC dyscrasia patients 
detected circulating tumor cfDNA with a median of 11000 haploid genome-equivalents per mL and 
more than 90% of the target region was covered over 1000X in all plasma samples. Overall, within 
the interrogated genes, 64% of patients harbored somatic mutations that were detectable in 
plasma cfDNA. Overall, the molecular spectrum of mutations discovered in cfDNA (NRAS in 25%; 
KRAS in 14%; TP53, TRAF3 and FAM46C in 11%, respectively; CYLD and DIS3 in 7%, respectively; and 
BRAF and IRF4 in 4% of cases, respectively) reflected previus observations in genomic studies based 
on PC genotypinf, thus supporting the tumor origin of the mutations identified in cfDNA . 
Our results provide the proof of principle that cfDNA genotyping is a feasible, non-invasive, real-
time approach that reliably detects clonal and subclonal somatic mutations represented in at least 
5% of alleles in tumor PCs. This limit is explained by the fact that the ctDNA is diluted in cfDNA from 
normal cells102, 156, and variants that are already rare in tumor gDNA are much less represented in 
plasma and may fall below the sensitivity threshold of the CAPP-seq.  
Despite the genetic heterogeneity characterizing MM, and the inclusion in the study cohort of 
seven patients at pre-malignant/asymptomatic disease stages, the designed gene-panel employed 
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in our study proved to be very effective, in that it allowed the recovery of at least one mutation in 
tumor gDNA of 20/28 (71%) cases. In none of the cases cfDNA genotyping identified additional 
somatic mutations not detected in the purified BM PCs, thus suggesting that, as far as our limited 
patient cohort is concerned, the genotype of PC collected from a single tumor site is already 
representative of the entire tumor genetics. Alternatively, spatial genomic heterogeneity, 
supported by very recent findings in MM157, may exist but involving minor subclones not sufficiently 
represented to be detectable in plasma. 
One of the original findings of the study is that cfDNA genotyping can resolve tumor genetics also 
in cases at early disease stages as MGUS and sMM patients, who may benefit the most from this 
minimally-invasive approach. Indeed, among asymptomatic patients cfDNA genotyping could allow 
a non-invasive longitudinal molecular monitoring of clonal evolution of the neoplastic clone and 
the identification of the switch point on which the disease acquires high-risk genetic features. This 
has been prevented so far by the unfeasibility of serial BM sampling in the clinical routine. In my 
opinion, this study enhances the growing evidence supporting the use of the liquid biopsy for a 
variety of clinical and investigational applications not previously possible. An immediate clinical 
application of cfDNA genotyping in MM could be the incorporation of this minimally invasive 
method in clinical trials for the identification of patients carrying actionable mutations and their 
longitudinal genetic monitoring during targeted therapy administration or for the estimation of 
minimal residual disease. 
In conclusion, the results of our study confirm and extend the mutational landscape of PC tumors, 
sustaining also the clonal heterogeneity of these diseases. These characteristics may obviously be 
a hindrance in the perspective of therapies directed against specific single targets, expected to act 
only on the subclone harbouring the particular genetic lesion. To overcome this obstacle, it would 
be as minimum necessary to combine different kind of treatments, each targeting different 
subclones. From this point of view, the application of the of NGS-based technologies in the 
diagnosis an follow-up of PC dyscrasias may help to clarify the mutational landscape of the 
diseases,.allowing to select specific treatment that may be beneficial to the patient, or, if not, to be 
avoided. In this scenario, the introduction of circulating tumor DNA genotyping would represent a 
feasible, non-invasive, real-time approach to the disease monitoring. 
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